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TSPO 18-kDa translocator protein 
ADAM A disintegrin and metalloproteinases 
ABCA1 Adenosine triphosphate-binding cassette transporter A1 
AD Alzheimer’s disease 
APP Amyloid precursor protein 
Aβ Amyloid-β 
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ERK Extracellular signal-regulated kinases 
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GWAS Genome wide association studies 
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HSTK Herpes simplex virus thymidine kinase 
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ITAM Immunoreceptor tyrosine-based activation motifs 
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IBA1 Ionized calcium binding adaptor molecule 1 
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LDLR Low-density lipoproteins receptor 
LRP Lipoprotein receptor-related protein 
MRI Magnetic resonance imaging 
MGnD Microglia of neurodegenerative phenotype 
NFT Neurofibrillary tangles 
NF Nuclear factor 
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PI3K Phosphoinositide 3-kinase 
PET Positron emission tomography 
PS1 Presenilin 1 
PS2 Presenilin 2 
PrPSC PrP-scrapie 
sAPPα Secreted APPα 
sTREM2 Soluble TREM2 
SYK Spleen tyrosine kinase 
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Alzheimer’s disease (AD) is the most common cause of dementia and presents a growing 
challenge to global health. AD is pathologically characterised by extracellular amyloid plaques 
(Aβ) and intraneuronal neurofibrillary tangles. Another key pathological feature of AD is 
chronic neuroinflammation suggesting that microglia, the major immune cell type in the brain, 
play an important role in AD progression. These pathological features have been known for 
over 115 years, yet the underlying mechanisms that connect these pathologies and result in AD 
are still unknown. Extensive evidence from recent genome wide association studies suggest 
that the innate immunomodulatory receptor, the triggering receptor expressed on myeloid cells-
2 (TREM21), plays a crucial role in sustaining the microglial response to disease pathogenesis. 
TREM2 is second only to apolipoprotein E (APOE2), the strongest genetic risk factor of AD, 
in terms of the magnitude of its effects as a late-onset AD risk factor.  
Studies using AD mouse models show that Trem2 is selectively expressed in microglia that 
cluster around Aβ plaques and is required for a variety of important microglial functions related 
to phagocytosis of cellular debris and Aβ fibrils. Although loss of Trem2 expression in AD 
mouse models was reported to decrease Aβ-associated microglia, contradictory effects on Aβ 
pathology were published. Therefore, to study the effects of TREM2 on premature Aβ plaque 
formation and deposition, I experimentally induced cerebral amyloidosis by stereotaxically 
injecting brain extract from aged Aβ plaque-bearing APPPS1 mice into the hippocampi of 
APPPS1/Trem2+/+, APPPS1/Trem2-/-, and APPPS1/Trem2p.T66M mice, at an age when no 
plaques had yet formed. I used APPPS1/Trem2p.T66M mice as an additional loss of Trem2 
function control as I, together with Gernot Kleinberger, published that the frontotemporal 
dementia-like disorder-associated p.T66M mutation reduces soluble Trem2 levels in vivo as a 
result of impaired Trem2 maturation and shedding (Kleinberger et al., 2017). Using this 
experimental paradigm, I found that Aβ seeding was significantly increased in the loss of 
Trem2 function APPPS1 mice compared to controls. I also confirmed that Trem2-deficiency 
impaired the capacity of microglia to remove Aβ seeds, most likely due to reduced IBA1- and 
CD68-positive microglia around plaques. Similar increase in plaque deposition and reduction 
in microglial activity was observed in Trem2-deficient APPPS1 mice during aging using 
longitudinal positron emission tomography. Surprisingly, while the rate of amyloidogenesis in 
Trem2-deficient APPPS1 mice consistently contradicted APPPS1/Trem2+/+ controls 
throughout aging, the plaque deposition in both models levelled out at 12 months. These data 
indicate that additional factors may influence Aβ accumulation, including its aggregation and 
clearance during aging. Moreover, the seeded plaque morphology in loss of Trem2 function 
APPPS1 mice appeared diffuse with less compact cores despite the increase in total Aβ burden. 
This was contradictory to what I expected considering that the reduction in microglial clearance 
of Aβ plaques may instead result in increased cored aggregates due to decreased phagocytosis 
of the plaque halo. 
                                                          
1 TREM2 – Human ortholog for gene and protein. Italicized for gene. Also used to describe the protein 
generally. Trem2 – Mouse ortholog for both gene and protein. 
2 APOE – Human and mouse ortholog. Italicized for gene. Also used to describe the protein generally. 
 ApoE – human and mouse ortholog to describe the protein. 
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Two recent studies independently reported that TREM2 binds to APOE and APOE mRNA 
expression is upregulated in plaque-surrounding microglia similarly to TREM2, suggesting 
that the TREM2-APOE interaction may regulate the microglial phenotypic changes in AD. As 
APOE is known to strongly localise with Aβ dense core plaques in AD as well as affect Aβ 
aggregation and clearance, I hypothesized that plaque-associated microglia may be critical to 
mitigating amyloid metabolism by inadvertently promoting Aβ aggregation in attempt to clear 
Aβ instead. To address this hypothesis, I performed three different sets of experiments. Firstly, 
I performed immunohistochemical analyses on exogenously seeded, that is, Aβ brain extract 
injected, as well as aged APPPS1 mice, with and without functional Trem2. By performing 
costainings for ApoE, Aβ, IBA1-expressing microglia and GFAP-expressing astrocytes, I 
observed a dramatic decrease in plaque-associated ApoE levels upon loss of Trem2 function 
in both seeded and aged mice. I found that compared to loss of Trem2 function mice, the IBA1-
positive microglia around plaques in APPPS1/Trem2+/+ showed a strong colocalisation with 
ApoE, whereas no Trem2-dependent changes in ApoE/GFAP colocalisation was detected. This 
was unexpected considering ApoE is reported as mainly being produced by astrocytes and only 
to a lesser extent in microglia. Secondly, in a collaborative effort, we analysed microglia-
enriched and microglia-depleted fractions in APPPS1 mice, the latter fraction containing 
mostly astrocytes as well as oligodendrocytes and neurons to a lesser extent, to compare 
relative ApoE protein induction in these fractions using mass spectrometry. Indeed, the 
microglia-enriched fraction produced more ApoE in APPPS1/Trem2+/+ compared to 
APPPS1/Trem2-/- mice. Microglia-depleted fractions in these mice did not show any Trem2-
dependent effects, suggesting that while ApoE may mainly be synthesized by astrocytes under 
healthy physiological conditions, microglia may contribute to the overall ApoE production in 
the brain during inflammation. Thirdly, to confirm these findings, I compared plaque-
associated ApoE levels and its glial origin in microglia-depleted APPPS1 mice to age-matched 
controls. ApoE was significantly reduced upon microglia-depletion, indicating that the ApoE 
content in plaques may largely derive from disease-associated microglia. Lastly, to test whether 
these preclinical findings could be translated to humans, I investigated microglia clustering 
around Aβ plaques and its ApoE content in AD patients with different TREM2 coding variants. 
AD patients with TREM2 variants presented impaired microglial association to plaques as well 
as reduced ApoE levels compared to AD cases with the common TREM2 variant, regardless of 
their APOE genotype.  
Taken together, my studies provide the first evidence that loss of Trem2 function not only 
increases early plaque formation due to impaired microglial phagocytosis, but also alters 
the kinetics of amyloidogenesis during aging. In addition, I found that ApoE protein levels 
are strongly induced in plaque-associated microglia under disease conditions in a Trem2-
dependent manner. While the ApoE contribution of astrocytes cannot be completely 
excluded, microglia-depletion in mice and loss-of-function TREM2 coding variants in AD 
patients drastically reduce ApoE in plaques, which in turn may affect Aβ metabolism. 
These results suggest that the TREM2-APOE interaction may initially serve as protective 
means to modulate Aβ plaque clearance but in parallel may exacerbate Aβ pathology. 
Therefore, any therapeutic strategy attempting to target microglial function to modulate 




Die Alzheimer-Krankheit (AD) ist die häufigste Ursache für Demenz und stellt eine wachsende 
Herausforderung für die globale Gesundheit dar. AD ist pathologisch durch extrazelluläre 
Amyloid-Plaques (Aβ) und intraneuronale neurofibrilläre Bündel gekennzeichnet. Ein weiteres 
pathologisches Merkmal von AD ist die chronische Neuroinflammation, was darauf hindeutet, 
dass Mikroglia, der wichtigste Typ von Immunzellen im Gehirn, eine bedeutende Rolle bei der 
AD-Progression spielen. Obwohl diese pathologischen Merkmale seit über 115 Jahren bekannt 
sind, sind die zugrunde liegenden Mechanismen, die zu diesen Pathologien und zu AD führen, 
weiterhin unbekannt. Umfangreiche Beweise aus kürzlich durchgeführten genomweiten 
Assoziationsstudien legen nahe, dass der angeborene immunomodulatorische Rezeptor, der auf 
myeloischen Zellen-2 (TREM2) exprimiert wird, eine entscheidende Rolle bei der 
Aufrechterhaltung der Mikroglia-Reaktion und der  Pathogenese der Erkrankung spielt. 
Darüber hinaus steht TREM2an zweiter Stelle hinter Apolipoprotein E (APOE), dem stärksten 
genetischen Risikofaktor von AD, was die Stärke seiner Auswirkungen als spät einsetzender 
AD-Risikofaktor angeht. 
Studien mit AD-Mausmodellen zeigen, dass Trem2 selektiv in Mikroglia exprimiert wird, die 
sich um Aβ-Plaques herum ansammeln, und für eine Vielzahl wichtiger Mikrogliafunktionen 
benötigt wird, die mit der Phagozytose von Zelltrümmern und Aβ-Fibrillen zusammenhängen. 
Obwohl berichtet wurde, dass der Verlust der Trem2-Expression in AD-Mausmodellen die Aβ-
assoziierten Mikroglia verringert, wurden widersprüchliche Auswirkungen auf die Aβ-
Pathologie veröffentlicht. Um die Auswirkungen von TREM2 auf die Bildung und Ablagerung 
von neu entstandenen Aβ-Plaques zu untersuchen, induzierte ich daher experimentell die 
cerebrale Amyloidose durch stereotaktisches Injizieren von Hirnhomogenat aus gealterten 
APPPS1-Mäusen in die Hippocampi von APPPS1/Trem2+/+ sowie, APPPS1/Trem2-/- und 
APPPS1/Trem2p.T66M Mäusen in einem Alter, in dem sich noch keine Plaques gebildet haben. 
Ich verwendete APPPS1/Trem2p.T66M Mäuse als zusätzliche Kontrolle zum Verlust der Trem2-
Funktion, da ich zusammen mit Gernot Kleinberger veröffentlichte, die mit der 
frontotemporalen Demenz-ähnlichen Störung assoziierte p.T66M-Mutation in vivo lösliche 
Trem2-Spiegel reduziert, als Folge einer beeinträchtigten Trem2-Reifung und -Spaltung 
(Kleinberger et al. 2017). Darüber hinaus fand ich heraus, dass ‚Aβ-Seeding‘ in den 
APPPS1/Trem2-/- und APPPS1/Trem2p.T66M-Mäusen im Vergleich zu den APPPS1/Trem2+/+ 
Kontrollen signifikant erhöht war. Mit diesem Modell bestätigte ich auch, dass der Trem2-
Mangel die Fähigkeit von Mikroglia zur Entfernung von ‚Aβ-Seeds‘ beeinträchtigt, 
höchstwahrscheinlich durch reduzierte IBA1- und CD68-positive Mikroglia um Plaques. Ein 
ähnlicher Anstieg der Plaqueablagerung und der Verringerung der Mikroglia-Aktivität wurde 
während des Alterns bei Trem2-defizienten APPPS1-Mäusen unter Verwendung der 
longitudinalen Positronenemissionstomographie beobachtet. Während die Geschwindigkeit 
der Amyloidogenese bei Trem2-defizienten APPPS1-Mäusen während der gesamten 
Alterungsdauer entgegengesetzt zu den APPPS1/Trem2+/+ Kontrollen verlief, stagnierte die 
Plaqueablagerung bei beiden Mausmodellen überraschenderweise nach 12 Monaten.  Diese 
Daten weisen darauf hin, dass zusätzliche Faktoren die Aβ-Akkumulation und -Beseitigung 
beeinflussen können, und zwar der Stoffwechsel während des Alterns. Darüber hinaus schien 
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die induzierte Plaque-Morphologie beim APPPS1/Trem2-/- und APPPS1/Trem2p.T66M Mäuse 
trotz der Zunahme der gesamten Aβ-Belastung diffus mit weniger kompakten Kernen zu sein. 
Dies stand im Gegensatz zu dem was ich erwartete, da eine Verminderung des Abbaus von 
Aβ-Plaques durch Mikroglia ebenso zu vermehrten Kernaggregaten aufgrund einer erhöhten 
Aβ-Verfügbarkeit sowie einer verringerten Phagozytose des Plaque-Halos führen kann. 
Kürzlich berichteten zwei unabhängige Studien, dass TREM2 an APOE bindet und die APOE-
mRNA-Expression in Plaque-umgebender Mikroglia, ähnlich wie TREM2 hochreguliert, wird, 
was darauf hindeutet, dass die TREM2-APOE-Wechselwirkung die mikroglialen 
phänotypischen Veränderungen in AD regulieren könnte. Da bekannt ist, dass APOE mit 
dichten Aβ-Core-Plaques in AD stark lokalisiert ist und die Aβ-Aggregation und -Beseitigung 
beeinflusst, stellte ich die Hypothese auf, dass Plaque-assoziierte Mikroglia kritisch sein 
können, um den Amyloid-Metabolismus zu mildern, indem bei dem Versuch  Aβ  zu 
beseitigen, stattdessen versehentlich die Aβ-Aggregation begünstigt wird. Um dieser 
Hypothese nachzugehen, führte ich drei verschiedene Experimente durch. Zunächst führte ich 
immunhistochemische Analysen an exogen induzierten und gealterten APPPS1-Mäusen, mit 
und ohne funktionellem Trem2, durch. Durch die Durchführung von Parallelfärbungen für 
ApoE, Aβ, IBA1-exprimierende Mikroglia und GFAP-exprimierende Astrozyten, konnte ich 
eine dramatische Abnahme der Plaque-assoziierten ApoE-Spiegel nach Verlust der Trem2-
Funktion sowohl in injizierten als auch in gealterten Mäusen feststellen. Außerdem stellte ich 
fest, dass die IBA1-positiven Mikroglia um Plaques in APPPS1 im Vergleich zu 
APPPS1/Trem2-/- und APPPS1/Trem2p.T66M-Mäusen eine starke Kolokalisation mit ApoE 
zeigten, während keine Trem2-abhängige Veränderung der ApoE/GFAP-Kolokalisation 
festgestellt wurde. Dies war unerwartet, da zuvor berichtet wurde, dass ApoE hauptsächlich 
von Astrozyten produziert wird und nur in geringerem Maße in Mikroglia. Zweitens haben wir 
in gemeinschaftlichen Bemühungen mikroglia-angereicherte und mikroglia-depletierte 
Fraktionen in APPPS1-Mäusen analysiert, wobei die letztere Fraktion hauptsächlich 
Astrozyten sowie Oligodendrozyten und, in einem geringeren Ausmaß, Neuronen enthielt, um 
die relative Induktion von ApoE-Protein in diesen Fraktionen mittels Massenspektrometrie zu 
vergleichen. In der Tat erzeugte die mit Mikrogliazellen angereicherte Fraktion mehr ApoE in 
APPPS1/Trem2+/+ im Vergleich zu APPPS1/Trem2-/- Mäusen. Darüber hinaus zeigten die an 
Mikrogliazellen depletierten Fraktionen in diesen Mäusen keine Trem2-abhängigen Effekte, 
was darauf hindeutet, dass ApoE unter gesunden physiologischen Bedingungen zwar 
hauptsächlich durch Astrozyten synthetisiert werden kann, Mikroglia jedoch während einer 
Entzündung zur gesamten ApoE-Produktion im Gehirn beitragen können. Drittens, zur 
Bestätigung dieser Befunde, verglich ich die Plaque-assoziierten ApoE-Spiegel und ihren Glia-
Ursprung in Mikroglia depletierten APPPS1 Mäusen mit den altersüblichen APPPS1-
Kontrollen. Bei Mikroglia-Depletion fehlte ApoE nicht nur weitgehend in den Plaques, 
sondern zeigte auch eine signifikante Reduktion der IBA1/ApoE-Kolokalisationsfärbung. Es 
wurden keine Veränderungen der GFAP/ApoE-Kolokalisationen im Vergleich zu den 
Kontrollen beobachtet, was darauf hindeutet, dass der ApoE-Gehalt in Plaques weitgehend von 
krankheitsassoziierten Mikroglia herführen kann. Um zu testen, ob diese präklinischen 
Ergebnisse auf den Menschen übertragen werden können, untersuchte ich Mikroglia, die sich 
um Aβ-Plaques herum ansammeln, und deren ApoE-Gehalt bei AD-Patienten mit 
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verschiedenen TREM2-Codierungsvarianten. AD-Patienten mit TREM2-Varianten zeigten im 
Vergleich zu AD-Fällen mit der üblichen TREM2-Variante unabhängig von ihrem APOE-
Genotyp eine beeinträchtigte Mikrogliazellen-Assoziation mit Plaques sowie verringerte 
ApoE-Spiegel. 
Zusammenfassend liefern meine Studien den ersten Beweis dafür, dass der Verlust der 
Trem2-Funktion nicht nur die frühe Plaquebildung aufgrund einer gestörten 
mikroglialen Phagozytose erhöht, sondern auch die Kinetik der Amyloidogenese 
während des Alterns verändert. Darüber hinaus fand ich heraus, dass ApoE-
Proteinspiegel in Plaque-assoziierten Mikroglia unter Krankheitsbedingungen auf eine 
Trem2-abhängige Weise induziert werden. Während der ApoE-Beitrag von Astrozyten 
nicht vollständig ausgeschlossen werden kann, reduzieren Mikroglia-Depletion bei 
Mäusen und TREM2-Codierungsvarianten bei AD-Patienten ApoE in Plaques drastisch, 
was wiederum den Aβ-Metabolismus beeinflussen kann. Diese Ergebnisse legen nahe, 
dass die TREM2-APOE-Wechselwirkung anfänglich als Schutzmittel zur Modulation 
der Aβ-Plaque-Beseitigung dienen kann, parallel dazu jedoch die Aβ-Pathologie 
verschlimmern kann. Daher muss bei jeder therapeutischen Strategie, die versucht, die 
Mikrogliafunktion zur Modulation der Aβ-Pathogenese zu beeinflussen, die 















1 Alzheimer’s disease  
Alzheimer’s disease (AD) is a terminal, age-related neurodegenerative disease, which affects 
over 20 million people worldwide and is known to be the most common cause of dementia 
(www.alz.org/alzheimers-dementia). Given the accelerated aging of the population, the 
number of individuals with AD is predicted to increase dramatically and create a worldwide 
public health crisis (www.alz.org/alzheimers-dementia/facts-figures). AD is clinically 
distinguished by loss of memory and progressive decline in cognitive function. Current 
medications for AD only provide symptomatic relief by delaying cognitive decline, however 
there are no disease-modifying therapies available to intervene the course of AD dementia or 
delay its onset.  
 
Figure 1.1 Multifaceted pathology of AD. Amyloid-β (Aβ) plaques and tau aggregates are often found 
throughout the (A) AD brain, particularly in the temporal cortex upon post-mortem histological 
examination, compared to (B) healthy elderly brain. Ionized calcium binding adaptor molecule 1 
(IBA1)-positive microgliosis and glial fibrillary acidic protein (GFAP)-stained astrogliosis are often 
observed in AD. Arrows indicate areas of increased gliosis. Cortical and hippocampal brain areas are 
most commonly affected and begin to shrink with increasing severity of neurodegeneration as seen by 
enlarged ventricles in AD compared to healthy control. Red dotted area in the magnetic resonance 
imaging (MRI) scan shows significant hippocampal atrophy in AD patient compared to control. In vivo 
positron emission tomography (PET) images show increased Aβ and tau signal in AD compared to 
healthy cases. Similarly, increased 18-kDa translocator protein (TSPO) signal is observed due to 
increased gliosis and inflammation in the AD brain. (Adapted from (Higuchi et al., 2016)). 
Post-mortem AD brains present key histopathological hallmarks accompanied by widespread 
brain atrophy (Figure 1.1) (Braak and Del Tredici, 2011). These include aggregation and 
accumulation of extracellular Aβ plaques and intracellular tau neurofibrillary tangles (NFTs) 
(Figure 1.1). AD was initially considered a cell-autonomous neurodegenerative disorder, 
although Aβ and tau pathology is often accompanied by marked gliosis in AD patients and 
respective mouse models. In fact, Alois Alzheimer already illustrated the abnormal 
morphology of glial cells in the initial publication describing the disease (Alzheimer, 1907). 
Since then, extensive post-mortem immunohistochemical examinations illustrate abnormal 
protein aggregates that are often associated with activation of microglia and astrocytes 
(Ransohoff, 2016). Although AD is often accurately diagnosed only after death, recent 
biomarker and imaging studies indicate that AD pathology begins decades before the onset of 
clinical symptoms (Gonneaud et al., 2017, Insel et al., 2017, Suarez-Calvet et al., 2016a, 
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Suarez-Calvet et al., 2016b). Imaging modalities such as MRI provide detailed three-
dimensional structural information of the brain by using tissue characterisation with soft tissue 
contrast, while PET specifies functional and metabolic changes in the brain by detecting 
gamma rays emitted indirectly by a radioactive tracer (Zhang et al., 2017). Thus, a combination 
of PET/MRI has significantly improved our understanding of different stages of AD by 
measuring changes in Aβ and tau deposits as well as gliosis over time (Figure 1.1). Extensive 
neuroimaging studies involving a large cohort of AD patients at different disease stages imply 
that degrees of hippocampal atrophy, ventricular and whole-brain volumes can predict the 
disease progression (Fox et al., 2001, Gispert et al., 2016). To date, the cause of AD is not well 
understood. However, accumulating genetic and functional evidence strongly indicates an 
active role of brain innate immunity in AD pathogenesis and progression (Pimenova et al., 
2018). 
1.1 Early onset AD  
Aging is the greatest risk factor for sporadic AD (Guerreiro and Bras, 2015). Besides aging, 
environmental, epigenetic, and genetic factors contribute to the risk of developing AD. The 
majority of AD cases are sporadic with familial (FAD) cases accounting for less than 1% 
(Campion et al., 1999). This small percentage of autosomal dominant AD (ADAD) cases 
manifest with early dementia onset, typically between the age of 30 and 60 years old due to 
mutations in presenilin 1 (PS1), presenilin 2 (PS2) and amyloid precursor protein (APP). While 
presenilins are mainly known as the catalytic subunit of the γ-secretase complex, APP has 
several important physiological functions in neuronal plasticity, synaptic transmission, 
cognition and neuroprotection during brain development as well as in the mature and ageing 
brain (Muller et al., 2017, Richter et al., 2018, Rice et al., 2019, Haass and Willem, 2019). In 
the healthy brain, APP functions as a cell surface receptor-like protein or ligand and may 
mediate its effects from the cell surface or via its secreted proteolytic fragments, particularly 
secreted APPα (sAPPα) (Figure 1.2). However, APP mutations located within or immediately 
flanking the Aβ region of APPβ affect Aβ production or aggregation, for example by altering 
the proteolytic activity of β- and γ-secretases (Figure 1.2) (Citron et al., 1992). Mutations in 
components of the γ-secretase complex PS1 or PS2 also favour the amyloidogenic pathway by 
reducing the γ-secretase complex activity to increase Aβ42/40 ratio or by generating longer 
amyloidogenic peptides such as Aβ42 and Aβ43 (Saito et al., 2011, Kretner et al., 2016). 
Moreover, certain mutations in APP or PS do not necessarily affect Aβ production but may 
instead affect its hydrophobic properties and therefore its aggregation propensity and clearance 
(Tsubuki et al., 2003). For example, the London APP mutation (V717I) increases the Aβ40/42 
ratio by modifying the γ-secretase cleavage (Goate et al., 1991), while the Swedish mutation 
(K670N/M671L) enhances the β-secretase cleavage, thereby promoting Aβ production (Hardy 
and Selkoe, 2002). Additionally, the Icelandic APP mutation (A673T) based N-terminal to the 
β-secretase cleavage site not only reduces Aβ production, but also protects against AD (Jonsson 
et al., 2012). These findings suggest that Aβ plays an important role in the initiation and 




Figure 1.2 Proteolytic processing of APP. APP is a type 1 transmembrane protein with the carboxyl 
terminus within the cytosol and amino terminus within the extracellular space. In the non-
amyloidogenic pathway, APP is processed consecutively by α- and γ-secretases to yield sAPPα, p3, and 
the APP intracellular domain (AICD). However in the amyloidogenic pathway, APP is first cleaved by 
membrane-bound endoprotease β-secretase to release a large fragment called sAPPβ. The remaining 
membrane bound C99 fragment is sequentially cleaved by γ-secretase to yield Aβ peptides. The longer 
Aβ peptides, for example Aβ42 and Aβ43, are the more hydrophobic and aggregation-prone species that 
are commonly found in Aβ core plaques. Amyloid plaque cores composed of fibrillar Aβ in a β sheet 
conformation are surrounded by a halo of diffuse Aβ.  
1.2 Late onset AD 
Genome wide association studies (GWAS), a methodology that compares allele frequencies of 
polymorphisms between cases and controls, have identified many genetic risk factors 
implicated in increasing susceptibility for late onset AD (LOAD). The majority of AD cases 
clinically manifest later than FAD, that is, after the age of 60 but is pathologically identical to 
FAD. In the non-AD brain, the Aβ peptide is cleared from the brain via several means: (1) 
enzymatic degradation (Carson and Turner, 2002), (2) secretion across the blood brain barrier 
(BBB) (Cirrito et al., 2005, Ma et al., 2018), (3) glymphatic clearance system (Jessen et al., 
2015), or (4) microglia phagocytosis (Lee and Landreth, 2010). However, LOAD cases often 
display deficits in Aβ clearance and Aβ production (Figure 1.3) (Mawuenyega et al., 2010, 
Selkoe, 2001). For example, apolipoprotein E (APOE) – the strongest genetic risk factor for 
LOAD - modulates Aβ clearance and aggregation isoform-dependently (Castellano et al., 
2011, Holtzman et al., 2000). The APOE gene resides on chromosome 19 with three common 
alleles present in the human population: ε2 (Cysteine 112, Cysteine 158), ε3 (Cysteine 112, 
Arginine 158) and ε4 (Arginine 112, Arginine 158). The ε4 allele is associated with an 
increased risk, whereas ε2 is relatively protective compared to the ε3 allele. A single copy of 
ε4 increases AD risk by ~3-fold, while two copies increases the risk by ~12-fold, thereby 
affecting the age of onset and disease severity significantly (Corder et al., 1993, Saunders et 
al., 1993). More than 50% of LOAD patients carry at least one copy of the ε4 allele. 
Homozygous ε4/ε4 individuals include 15% of LOAD cases, however only 2% of the healthy 
population are ε4/ε4 carriers (Farrer et al., 1997). Although carrying the ε4 haplotype does not 
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necessarily guarantee that an individual will develop LOAD, the ε4 isoform appears to affect 
brain function associated with both altered neurological and metabolic functions decades prior 
to any clinical symptoms becoming obvious (Filippini et al., 2009, Michaelson, 2014) (further 
discussed in section 4.0).  
Over 50% of GWAS-identified risk factors are involved in microglial and innate immune cell 
function, some of which include ABCA7, ABI3, CD33, CLU, CR1, MS4A4A, and PLCγ2 
(Harold et al., 2009, Lambert et al., 2013, Naj et al., 2011, Sims et al., 2017, Hollingworth et 
al., 2011). Additionally, the triggering receptor expressed on myeloid cells type 2 (TREM2) 
significantly impacts the risk of LOAD with similar odds ratio to the single APOE ε4 allele 
(Guerreiro et al., 2013a). Innate immunity is an indispensible component in AD pathogenesis 
as chronic glial activation is a prominent feature accompanying pathological protein 
accumulation in the AD brain. Moreover, immune cells such as microglia and astroglia that 
react to disease-associated protein aggregates may not simply be bystanders, but may instead 
contribute to AD pathogenesis (Wyss-Coray and Rogers, 2012). For example, long-lasting 
inflammation may cause neuronal damage and death via several mechanisms, such as: (1) 
release of toxic substances including reactive oxygen species and nitric oxide, (2) enhanced 
expression of “eat-me” signals including phophatidylserine and calreticulin which induce 
phagoptosis, (3) activation of complement system to induce cell lysis, and (4) activation of 
inflammasomes (Shi and Holtzman, 2018). Thus, Aβ build-up due to impaired innate immune 
cell functions may serve as a driving force for disease progression by influencing 
neurodegeneration. 
1.3 Amyloid cascade hypothesis 
The amyloid cascade hypothesis is strongly supported by genetic evidence not only from FAD 
cases, but also because multiple copies of APP cause ADAD with cerebral amyloid angiopathy 
(CAA) (Rovelet-Lecrux et al., 2005) or Down’s syndrome (Delabar et al., 1987) with increased 
accumulation of Aβ peptides. The hypothesis proposes that excessive Aβ peptide 
accumulation, particularly of the longer, more aggregation-prone Aβ species, is the causative 
agent in AD pathology that sets of a series of downstream events that ultimately leads to 
dementia and neurodegeneration (Hardy and Selkoe, 2002, Selkoe, 1991, Hardy and Higgins, 
1992) (Figure 1.3). For example, the build-up of extracellular Aβ aggregates may result in 
increased oxidative and endoplasmic reticulum (ER) stress as well as disrupted ionic 
homeostasis, which may create an imbalance of phosphatases and kinases that stimulate the 
hyperphosphorylation of tau, enhance vascular and neuronal damage, and induce widespread 
neuroinflammation observed as the disease progresses (Hardy and Selkoe, 2002, Haass and 
Selkoe, 2007). However, the hypothesis has also been criticized as not all observations 
necessarily fit. For instance, early symptoms of dementia and neuronal loss have been more 
closely linked to amount of NFT deposits rather than Aβ plaques (Arriagada et al., 1992, 
Musiek and Holtzman, 2015). Additionally, Aβ plaques appear to be neurotoxic particularly in 
the presence of NFTs (Rapoport et al., 2002). These seemingly contradicting findings may be 
explained by the prerequisite of Aβ oligomers or deposits to be initially present to consequently 
trigger tau-mediated toxicity (Haass and Selkoe, 2007). Nonetheless, while rare variants in the 
microtubule associated tau-encoding gene have been linked to tauopathies, such as 
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frontotemporal dementia (FTD) (Hutton et al., 1998, Neumann et al., 2009), AD onset is 
primarily influenced by genetic variations affecting Aβ production (Hardy and Allsop, 1991, 
Hardy and Higgins, 1992). On the other hand, the presence of senile Aβ plaques in the absence 
of cognitive abnormalities suggests that Aβ may not necessarily initiate the downstream events 
but may instead be associated with aging (Bennett et al., 2006, Morris et al., 2010). Although, 
why would Aβ in AD patients act differently compared to healthy elderly cases? Several 
immune cell receptors expressed particularly on microglia in the brain are responsible for 
engulfing and degrading Aβ plaques. Many of these microglial receptors, including TREM2, 
have been recently linked to increased LOAD risk (discussed in section 1.2), suggesting that 
the difference in AD patients and healthy aging cases may be the failure of microglia to 
appropriately respond to the pathogenic Aβ. Therefore, the inability to remove the initial threat 
in time becomes increasingly destructive leading to overwhelming Aβ production as well as 
loss of microglial function (discussed in section 2). In parallel, the accumulating Aβ may 
trigger an inflammatory response leading to increased free reactive oxygen species and a 
cytokine profile that promotes neuroinflammation, synaptic degradation and 
neurodegeneration (Wyss-Coray and Rogers, 2012) (further discussed in section 2.0). Thus, 
the microglia-Aβ interaction may significantly impact AD onset and severity as a consequence 
of an imbalance between Aβ-peptide production and clearance. 
 
Figure 1.3 Schematic representation of the amyloid cascade hypothesis.  
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1.4 Mouse models of amyloid pathology  
As there are no efficient naturally occurring animal models for AD, the discovery of APP and 
PS mutations in AD gave rise to indispensable opportunities to study amyloidosis in transgenic 
mouse models harbouring these mutations (Götz et al., 2004, Sasaguri et al., 2017, LaFerla and 
Green, 2012). Using “humanised” mice carrying human APP and PS variants can be used to 
not only investigate Aβ pathology and associated disease phenotypes, but also the affinity of a 
drug designed to bind to the relevant human protein (Sasaguri et al., 2017, Webster et al., 
2014). Ideally, animal models of AD should entirely recapitulate the complete human 
pathological scenario, that is, synaptic dysfunction and loss, progressive cognitive decline, 
amyloid plaques and NFT deposition, inflammation, neuronal death as well as brain atrophy 
(Sasaguri et al., 2017). However, current models recapitulate only certain aspects of the 
disease. For example, even though many APP and PS1 mouse models exhibit extracellular Aβ 
deposits, reminiscent of plaques in the human AD brain, to date none of the amyloidogenic 
transgenic mouse models show aggregated tau deposits or neuronal loss in the brain. 
Several Aβ-depositing mouse models have been extensively studied, some of which include 
PDAPP (Games et al., 1995), Tg2576 (Hsiao et al., 1996), APP23 (Sturchler-Pierrat et al., 
1997), J20 (Mucke et al., 2000), TgCRND8 (Chishti et al., 2001), APP/PS1dE9 (Jankowsky 
et al., 2004) and APP/PS1 (Radde et al., 2006) among many others. Most amyloid mouse 
models currently available overexpress one or more of the FAD mutations such as the London 
or Swedish mutations. As a result, these mice develop substantial Aβ deposits between 6-11 
months of age, eventually displaying progressive plaque-associated gliosis and dystrophic 
neurites with age (Sasaguri et al., 2017). Certain APP transgenic mouse models, such as the 
Swedish mutation-overexpressing mice, show apparent behavioural deficits at a young age 
compared to wild-type (WT) mice. Even though PS1 mutations cause the majority of FAD 
cases (Karch et al., 2014), overexpression of mutant PS1 or a knock-in of the human gene 
mutation alone fails to induce Aβ pathology in mice. This may most likely be due to insufficient 
production of pathogenically longer Aβ species (De Strooper et al., 1995). Alternatively, the 
difference in three amino acids in murine Aβ1-42 sequence from human Aβ reduces the 
amyloidogenic potential of murine Aβ to self-aggregate as well as its degree of neurotoxicity 
(Chui et al., 1999, Guo et al., 1999, Schmitz et al., 2004, Xu et al., 2015). Thus, Aβ pathology 
in transgenic mouse models is only induced with the overexpression of both mutated human 
APP and PS, such as Tg2576 and PS1M146L (Holcomb et al., 1998), APPKM670/671NL and 
PSA246E (Borchelt et al., 1997), APP KM670/671NL and PS1 deltaE9/S290 (Jankowsky et 
al., 2004), APP KM670/671NL and PS1 L166P (Radde et al., 2006), and others.  
Overexpressing several transgenic insertions may destroy the endogenous gene loci (Saito et 
al., 2016) and overproducing APP fragments unrelated to Aβ may interact abnormally with 
cellular proteins leading to artefacts (Mitani et al., 2012, Saito et al., 2016). To overcome the 
drawbacks of APP overexpression paradigm, APP knock-in mice were generated to 
overproduce pathogenic Aβ42 without changing APP expression (Saito et al., 2014). For this, 
the authors inserted humanised Aβ region containing two or three APP mutations (Swedish 
KM670/671NL and Beyreuther/Iberian I716F mutations, respectively) into the endogenous 
murine APP gene resulting in increased Aβ plaque deposition and high Aβ40/42 ratio (Saito et 
al., 2014). The Beyreuther/Iberian mutation increases the Aβ40/42 ratio by 30-fold 
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(Lichtenthaler et al., 1999), which was later identified as an aggressive form of FAD in Iberia 
(Guerreiro et al., 2010). Although the APP knock-in model may offer an improved mouse 
model for FAD, the mice do not develop fibrillar core Aβ plaques until much later in age, with 
almost no vascular pathology compared to the APP and PS1 double transgenic mice. Thus, the 
APP overexpression and knock-in mice each independently present distinct advantages and 
disadvantages depending on the aim of the experiment. 
1.4.1 The APPPS1 mouse model 
APPPS1 mice (line 21) carry human transgenes for the Swedish APP mutation 
(K670N/M671L) and PS1 (L166P) mutation. Both genes are expressed under thymidine 1 
(Thy.1) promoter to ensure high levels of neuron-specific transgene expression in the postnatal 
brain (Radde et al., 2006). The human APP transgene is expressed approximately 3-fold higher 
than the endogenous murine APP, and mainly expressed in neocortical, hippocampal, and brain 
stem neurons. Consequently, APP overexpression results in roughly 3-fold increased Aβ 
generation compared to WT mice due to enhanced β-secretase cleavage (Radde et al., 2006). 
The aggressive PS1 L166P mutation, which causes onset of AD as early as 24 years of age 
(Moehlmann et al., 2002, Bentahir et al., 2006), favours the production of human Aβ42 over 
Aβ40, all of which increase with age (Li et al., 2016).  
 
Figure 1.4 Microglia clustering around Aβ plaques. Left: Aβ plaques (red) and microglia (brown) 
stained temporal cortex of an AD case. Scale bar - 100μm. Right: Aβ plaques (magenta) and microglia 
(green) stained in APPPS1 mouse cortex. Scale bar - 20μm. Insets show a higher magnification of the 
area indicated in white dotted boxes. (Experiments performed and imaged by S. Parhizkar). 
Amyloid plaque deposition starts in the neocortex at six weeks of age (Radde et al., 2006). 
Despite their small size, nearly 100% of the plaques are congophillic in nature. Deposits in the 
hippocampus appear at around three months of age in males and four months in females. 
Congophillic plaques are also observed in the striatum, thalamus and brain stem after five 
months of age. By eight months, these mice exhibit substantial plaque load with the majority 
of plaques consisting of a dense core surrounded by a diffuse halo, resembling plaques 
observed in the human AD brain (Figure 1.4). Tau-positive neuritic processes are present at 
later stages in proximity to dense cored plaques, however fibrillar tau inclusions fail to 
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accumulate (Radde et al., 2006). Moreover, microgliosis and astrogliosis are often observed in 
plaque-bearing regions similar to the AD brain (Figure 1.4). Additionally, cognitive 
impairments manifest around six to eight months of age, often presented by deficits in spatial 
learning and memorizing a maze task (Radde et al., 2006, Serneels et al., 2009). Neuron loss 
is largely absent in this mouse model, with only modest loss found in the granule cell layer of 
the dentate gyrus after 15 months of age (Rupp et al., 2011). 
Besides investigating Aβ pathology in the brain, the Aβ levels in cerebrospinal fluid (CSF) 
have also been extensively studied (Bacioglu et al., 2016, Maia et al., 2013). Aβ42 and Aβ40 
levels in CSF decrease with age by approximately 80% and 45%, respectively. This reduction 
in Aβ levels strongly correlates with increased Aβ aggregates depositing in the brain. 
Additionally, the total tau concentrations increase at six months, reaching a 5-fold increase by 
18 months of age (Maia et al., 2013). Altogether, these findings in the APPPS1 mouse model 
closely corroborate the amyloid pathology observed in AD patients (Figure 1.4), and therefore 
serve as a suitable system to study amyloidosis-related pathomechanisms allowing relatively 
rapid experimental readouts. 
1.5 The prion paradigm – Propagation of proteopathic seeds 
Numerous studies on the role of protein aggregation in neurodegenerative diseases have 
speculated that the essential cause of neuronal dysfunction and death may result from 
cumulative protein misfolding and aggregation (Goedert et al., 2017, Walker and Jucker, 
2015). Although neurodegenerative diseases such amyotrophic lateral sclerosis (ALS), 
Parkinson’s disease, FTD and AD present different pathological and clinical characteristics, 
the diseases share a central pathogenic mechanism: the seeded aggregation of disease-specific 
proteins (Prusiner, 2012, Jucker and Walker, 2013, Guo and Lee, 2014). The prion paradigm 
proposes that assemblies of misfolded protein act as seeds for the template misfolding of other 
uncorrupted molecules (Figure 1.5). The seeds may be the agents by which the aggregates 
proliferate and spread elsewhere in the brain, once again initiating seeding and thereby 
sustaining the disease process (Prusiner, 1984, Gajdusek, 1994). The hypothesis arose from 
decades of research on a group of proteinaceous infectious diseases, known collectively as 
transmissible spongiform encephalopathies (Collins et al., 2004). Prusiner and colleagues 
showed that prions are infectious agents consisting of abnormally folded prion protein (PrP) 
(Prusiner, 1982). Initially, prion diseases were thought to be present in humans only, e.g. 
Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker disease, kuru and fatal insominas. 
However, during the years several rare human spongiform encephalopathies were found to be 
transmissible to nonhuman primates (Gajdusek, 1977), for example scrapie in sheep, chronic 
wasting disease of deer and elk, bovine spongiform encephalopathy, and others (Caughey et 
al., 2009, Prusiner, 1998). Prion diseases are best known for their infectivity, however they can 
also be genetically heritable or sporadic in origin (DeArmond and Prusiner, 1995), similar to 
AD. Under normal conditions, the cellular prion protein (PrPC) assumes a nonpathogenic α-
helical conformation with little β-sheet. The disease manifests when PrPC molecules misfold 
into a shape abnormally enriched in β-sheet – similar to Aβ peptide in AD, and propagate 
through the nervous system after self-assembly. This corrupted form of PrP is called PrP-
scrapie (PrPSc). An important characteristic of misfolded prion protein is its enhanced potential 
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to form amyloid, that is, abnormal quantities of fibrillar protein (DeArmond and Prusiner, 
1995). Thus, similarities in biophysical properties of amyloidogenic proteins suggest that 
diseases characterised by abnormal protein deposition share certain etiological mechanisms 
(Gajdusek, 1994, Lansbury, 1997, Prusiner, 1998, Trojanowski and Lee, 1998, Goedert et al., 
2017).  
 
Figure 1.5 Prion-like template and seeding. A small portion of pathological seeds act as a template 
to induce misfolding and aggregation of the soluble protein, similar to the way amyloid fibril formation 
is accelerated upon addition of pre-formed pathological seeds in vitro (Harper et al., 1997, Hasegawa 
et al., 1999). The initial lag phase of the primary nucleation step follows a secondary nucleation step, 
during which existing fibrils are broken down into smaller fragments that become the building blocks 
for further seeding of soluble peptide monomers. Therefore, the second step not only depends on the 
rate at which the fibrils are created but also the availability of the soluble peptide monomers (Jarrett 
and Lansbury, 1993, Knowles et al., 2009). Thus, new preformed seeds can facilitate the formation of 
larger multimeric amyloid fibrils. (Adapted from (Goedert, 2015)).  
1.5.1 Amyloid seeding 
AD is not a classic prion disease, but shares several similarities. Aβ peptide multimerisation is 
long known to be an early and central process in the pathogenic cascade in AD (Selkoe, 2003, 
Hardy and Selkoe, 2002). However, little is known about the mechanisms that govern the 
initiation of Aβ aggregation and deposition in vivo. In the late 80’s, several groups performed 
inoculation experiments to test the hypothesis that AD, like spongiform encephalopathies, was 
transmissible (Goudsmit et al., 1980, Baker et al., 1993). Baker et al showed that intracerebral 
injections of AD brain homogenate into marmoset monkeys led to increased senile plaque load, 
however only after a long incubation period of approximately six to seven years. Moreover, 
the inductive agent as well as the mechanism of action remained unknown (Baker et al., 1993). 
As the first APP transgenic mouse models became available (Games et al., 1995, Hsiao et al., 
1996, Sturchler-Pierrat et al., 1997), Aβ seeding experiments were carried out to determine 
whether Aβ deposits could be generated de novo in a prion-like manner. Brain extracts from 
autopsy-derived AD patients and controls were stereotaxically injected into the hippocampal 
formation and overlying neocortex in young, predepositing APP-transgenic mice (Meyer-
Luehmann et al., 2006, Walker et al., 2002, Kane et al., 2000). Three to five months post-
injection, fibrillar Aβ deposits increased significantly at a point when the transgenic model 
would not yet have begun to develop endogenous Aβ plaques. Since then, the seeding paradigm 
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has been widely used in many different APP transgenic mice such as, Tg2576, APP23, APPPS1 
and 5xFAD as an inoculation model to induce Aβ aggregation and cerebral amyloidosis (Watts 
et al., 2014, Langer et al., 2011, Meyer-Luehmann et al., 2006, Kane et al., 2000, Morales et 
al., 2012, Rasmussen et al., 2017, Ziegler-Waldkirch et al., 2018). Additionally, the amyloid 
seeding model provides the unique opportunity to study plaque formation within a very defined 
and early time window. Furthermore, Aβ seeding activity persists for at least six months in the 
brain, even in the absence of template replication from host-derived Aβ (Ye et al., 2015a). The 
longevity of Aβ seeds in vivo suggests that they may act as resilient prion-like protein, which 
may provide novel insights into changes in brain activity preceding the onset of dementia in 
AD. 
The amyloid seeding model not only necessitates a donor extract containing Aβ seeds but also 
a host that can generate seeding-capable Aβ plaques. For example, injecting brain extracts from 
non-transgenic mice or non-AD control donors that lacked Aβ deposition failed to seed plaque 
formation (Meyer-Luehmann et al., 2006, Kane et al., 2000). Growing evidence supports the 
existence of variant structural strains of Aβ seeds, like tau (Falcon et al., 2015, Goedert, 2015) 
and PrP (Aguzzi et al., 2007, Collinge and Clarke, 2007, Prusiner, 2013). Injecting Aβ-rich 
brain extracts, which included Aβ monomers, oligomers, and larger multimeric Aβ species, 
from aged APP transgenic donor of the same strain as the host mice displayed a strain-specific 
seeding pattern (Meyer-Luehmann et al., 2006, Watts et al., 2011, Heilbronner et al., 2013). 
Moreover, different molecular Aβ conformations linked to their functionality have been 
detected in vivo. This was first observed immunohistochemically, which showed 
morphological changes in the Aβ staining pattern depending on the characteristics of both the 
APP-transgenic host and donor seeding extract (Meyer-Luehmann et al., 2006). Additionally, 
Aβ conformation-specific oligothiophene dyes confirmed that the molecular attributes of Aβ 
aggregates show intersubject variability among FAD and sporadic AD patients (Rasmussen et 
al., 2017, Condello et al., 2018). 
The extent of Aβ seeding is directly proportional to concentration of the injected brain extract 
(Meyer-Luehmann et al., 2006, Fritschi et al., 2014b). Additionally, the characteristics and rate 
of induced Aβ pathology further depend on the brain area injected, with strongest deposition 
in the entorhinal cortex and the hippocampal molecular layer, granular cell layer as well as the 
subgranular cell layer in the dentate gyrus (Walker et al., 2002, Meyer-Luehmann et al., 2006, 
Eisele et al., 2009). Ziegler-Waldkirch and colleagues were the first to show substantial 
neuronal death following Aβ deposition in vivo (Ziegler-Waldkirch et al., 2018). Using the 
amyloid seeding model, the authors found a dramatic decrease in proliferation and 
neurogenesis in the granular cell layer of dentate gyrus in two APP transgenic mouse models. 
These regions are also severely affected in aging transgenic mice under normal conditions 
(Radde et al., 2006). The selective vulnerability of these brain regions indicates that the starting 
point of the seeding cascade is crucial for the route or spread of pathology (Eisele et al., 2009, 
Meyer-Luehmann et al., 2006, Ziegler-Waldkirch et al., 2018). Furthermore, after injecting the 
seeding-competent brain extract into the hippocampus, Aβ deposits begin to appear in other 
brain regions throughout the hippocampal formation (Eisele et al., 2009) and limbic 
connectome over time (Ye et al., 2015b). As the limbic connectome is a major source of 
neocortical communication with the hippocampal formation and entorhinal cortex (Suh et al., 
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2011), these studies suggest that seeded Aβ aggregates traffic along neuronal pathways to 
spread pathology through the brain, similar to the cell-to-cell transmission model suggested in 
prion diseases (Lee et al., 2010). However, whether this occurs by random diffusion or by 
active, cell-specific uptake and transport is yet to be determined in vivo.  
Seeding most likely occurs due to the nature of Aβ deposits rather than additional factors that 
may indirectly stimulate Aβ aggregation, e.g. a virus or an immune response to the foreign 
brain extracts. To date, the seeding factors remain unknown; however several studies indicate 
that Aβ itself may drive the mechanism to a large extent (Heilbronner et al., 2013, Langer et 
al., 2011, Fritschi et al., 2014a, Fritschi et al., 2014b). Disrupting the amyloid-inducing activity 
of the injected brain extract by heating, reduced the Aβ induction (Meyer-Luehmann et al., 
2006). Additionally, denaturation of brain extracts by formic acid treatment or co-inoculation 
of anti-amyloid antibody abolished the seeding effect (Meyer-Luehmann et al., 2006, Duran-
Aniotz et al., 2014). These findings support the direct role of Aβ as the seeding agent. 
Preparation of synthetic Aβ40, Aβ42 or a mixture of both failed to induce detectable Aβ 
deposition (Meyer-Luehmann et al., 2006) unless the concentration was increased 10-fold with 
a longer incubation period (Stohr et al., 2012). Of note, the seeding potency of Aβ38 or Aβ43 
found in AD patients has not been reported. Furthermore, amyloid seeding has been attempted 
in an ex vivo hippocampal slice culture model, however it appears to be sustainable only upon 
frequent exposure to high levels of synthetic Aβ (Novotny et al., 2016), similar to PrP seeding 
potency (Miller et al., 2013, Wang et al., 2010). Moreover, ASC-deficient APP/PS1deltaE9 
display reduced seeding and spreading of Aβ, suggesting that the secreting adaptor protein 
ASC specks found in the core of amyloid plaques may play an active role in initiating cross-
seeding of Aβ plaques (Venegas et al., 2017).  
The seeding model has influenced other research fields, such as the aggregation and spreading 
of tau (Guo et al., 2016, Clavaguera et al., 2013), α-synuclein (Volpicelli-Daley et al., 2011, 
Luk et al., 2012) or TAR DNA-binding 43 protein found in frontotemporal lobar degeneration 
cases (Porta et al., 2018). Additionally, it has been used as an in vivo model for cross-seeding 
studies to investigate the interactions between amyloid and other proteopathic co-pathology 
such α-synuclein, or tau (Gotz et al., 2001, Bachhuber et al., 2015, Guo et al., 2013, He et al., 
2018, Venegas et al., 2017, Bolmont et al., 2007, Rasmussen et al., 2017). The seeding model 
has also been used to test treatment options such as immunization (Meyer-Luehmann et al., 
2006) or environmental enrichment as a non-pharmacological approach (Ziegler-Waldkirch et 
al., 2018). Finally, recent studies suggest that microglia may contribute to the transport and 
processing of seeds in a disease stage-dependent manner (Asai et al., 2015, Venegas et al., 
2017). 
2. Microglia and AD 
Microglia constitute approximately 10% of the total glial population in the healthy adult brain. 
Together with meningeal, choroid plexus, and perivascular macrophages, microglia 
compromise the brain myeloid cell population that plays a pivotal role in the CNS immune 
response and homeostasis. As the main innate immune cells of the CNS, microglia represent 
the first line of immunological defence by constantly surveying their microenvironment for 
signs of damage or debris allowing them to respond rapidly to focal injury or invading 
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pathogens (Davalos et al., 2005, Mazaheri et al., 2017). Microglia have several functions in 
the developing CNS, including (1) axon growth and synaptogenesis, (2) synaptic pruning, (3) 
angiogenesis, (4) support of neurogenesis, (5) recognising and responding to abnormal events 
including focal injury or neuropathological insults such as Aβ plaques, and (6) apoptosis and 
phagocytosis (Ransohoff, 2016). These functions are central to disease progression and 
modulation because chronic glial activation is a prominent feature of aging and often goes 
hand-in-hand with pathological protein accumulation as well as cell death, both of which 
constitute central characteristics of neurodegeneration. Although microglia’s response to injury 
is usually beneficial, it may also be detrimental, especially in chronic inflammation observed 
in AD (Hickman et al., 2008, Lucin and Wyss-Coray, 2009). 
2.1 Disease-associated microglia 
Depending on their microenvironment, microglia were considered to be selective to two states: 
resting or activated. Anti-inflammatory ramified microglia were described as resting, or M2, 
often observed during healthy physiological conditions and morphologically characterised by 
long processes and a small cell body. In contrast, the M1 activated amoeboid microglia were 
illustrated as hypertrophied cell bodies with short processes, and characterised by production 
of pro-inflammatory cytokines and nitric oxide (Wyss-Coray and Rogers, 2012). Ramified 
microglia were found throughout plaque-free brain regions, whereas the amoeboid microglia 
were typically associated with senile plaques (Brawek et al., 2014). However, recent advances 
in transcriptomics (Butovsky et al., 2014, Hammond et al., 2018, Keren-Shaul et al., 2017, 
Mazaheri et al., 2017, Krasemann et al., 2017) indicate that the M1/M2 dichotomy do not truly 
reflect the heterogeneous microglial populations present in disease-associated inflammation. 
Comprehensive single-cell RNA sequencing analysis of AD, ALS and aging mouse models 
show that microglia are present in a continuum of distinct phenotypes that are highly dependent 
on their spatiotemporal context (Kang et al., 2018, Hammond et al., 2018, Keren-Shaul et al., 
2017). For example, microglia heavily cluster around Aβ plaques in both mice and humans 
(Figure 1.3) (Meyer-Luehmann et al., 2008, Serrano-Pozo et al., 2013, Parhizkar et al., 2019) 
and modulate Aβ pathogenesis (further discussed in 3.3.1). These subset of microglia are called 
disease-associated microglia (DAM) (Keren-Shaul et al., 2017) or microglia of 
neurodegenerative phenotype (MGnD) (Krasemann et al., 2017). While DAM markers such as 
Clec7a, Cd68 and Cst3 are upregulated during disease conditions, homeostatic microglial 
markers such as P2ry12, P2ry13, and Cx3cr1 are downregulated (Keren-Shaul et al., 2017, 
Masuda et al., 2019). DAM typically display upregulation of genes involved in pathways 
triggering phagocytosis, migration and chemotaxis, as well as lysosomal and lipid metabolism 
such as ApoE, Lpl, Dap12, and Trem2 (Kang et al., 2018, Keren-Shaul et al., 2017, Krasemann 
et al., 2017, Mazaheri et al., 2017, Hammond et al., 2018, Masuda et al., 2019), all of which 
are well-known AD risk factors (Lambert et al., 2013).  
3. Triggering Receptor Expressed on Myeloid Cells 2 
TREM2 belongs to a family of innate immune receptors referred to as triggering receptors 
expressed on myeloid cells (Bouchon et al., 2000). In humans, the TREM2 gene is located on 
chromosome 6p21.1 or 17C in mouse and encodes a 230 amino acid glycoprotein. Many of the 
TREM and TREM-like (TREML) genes such as TREM1, TREML1, TREM2, TREML2, 
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TREML3, and TREML4 are conserved in mice and humans with only Trem3 and Trem6 unique 
to mice and TREML3 to humans. TREM2 is a type 1 cell surface transmembrane glycoprotein, 
and consists of an extracellular V-type immunoglobulin (Ig)-like domain as well as a short 
cytoplasmic tail (Figure 1.6) (Bouchon et al., 2000). It is selectively expressed on microglia in 
the brain (Sessa et al., 2004, Neumann and Takahashi, 2007), but also abundantly found in the 
periphery in a subgroup of myeloid cells, including bone osteoclasts, dendritic cells, alveolar 
and peritoneal macrophages, granulocytes and Kuppfer cells (Bouchon et al., 2001, Cella et 
al., 2003, Paloneva et al., 2003, Colonna and Wang, 2016). Trem2 expression levels increase 
with aging (Jay et al., 2015, Guerreiro and Hardy, 2013, Jiang et al., 2014, Brendel et al., 2017) 
and vary depending on the particular region of the CNS, with a higher expression in the white 
matter and hippocampus in the brain (Chertoff et al., 2013, Forabosco et al., 2013). High levels 
of Trem2 expression were reported in CD45-expressing cells (Jay et al., 2015, Savage et al., 
2015), suggesting that Trem2-expressing cells could be of a peripheral origin and may be found 
in the brain due to infiltrating monocytes. However, these findings were later disputed using 
parabiosis experiments in AD mouse model reporting that Trem2-expressing cells were mainly 
resident microglia rather than infiltrating monocytes (Wang et al., 2016). DAM often display 
elevated Trem2 expression in AD, ALS, and aging mouse models (Keren-Shaul et al., 2017, 
Krasemann et al., 2017). Keren-Shaul and colleagues revealed that DAM activation occurs in 
a Trem2-dependent manner during which microglia acquire a phagocytic phenotype associated 
with synthesis and degradation of lipids (Keren-Shaul et al., 2017). Moreover, microglia appear 
to be locked in a homeostatic state with impaired chemotaxis and reduced responses to neuronal 
injury in Trem2-deficient mice (Mazaheri et al., 2017).  
TREM2 binds to multiple ligands including microbial products, phospholipids, as well as 
zwitterionic and anionic lipids released during neuronal and glial damage to activate TREM2 
signalling (Figure 1.6). TREM2 mutations appear to blunt the signalling activity, suggesting 
that the positively charged arginine residue may be critical for initiating TREM2 signalling. 
Other ligands include nucleic acids, proteoglycans as well as heat shock protein 60 (Kober et 
al., 2016), which play an active role in phagocytosis (Stefano et al., 2009). Additionally, 
specific lipid species initiate TREM2 signalling, either as a lipoprotein complex or components 
of a cellular membrane (Cannon et al., 2012, Poliani et al., 2015, Song et al., 2016, Wang et 
al., 2015). For example, TREM2 binds to high-density lipoproteins (HDL), low-density 
lipoproteins (LDL) as well as apolipoproteins (Apo), such as ApoA1, ApoA2, ApoB, ApoE 
and ApoJ (also known as clusterin) in vitro (Yeh et al., 2016, Atagi et al., 2015, Bailey et al., 
2015, Song et al., 2016). ApoE lipidation does not appear to be essential for ApoE-TREM2 
binding to occur (Atagi et al., 2015, Bailey et al., 2015, Jendresen et al., 2017), although Yeh 
and colleagues reported that ApoE lipidation augmented this interaction (Yeh et al., 2016). 
Moreover, TREM2 appears to bind to all ApoE isoforms with similar affinities (Atagi et al., 
2015, Bailey et al., 2015). 
TREM2 is shuttled to and from the plasma membrane via the secretory pathway, that is, the 
trans-Golgi network (Prada et al., 2006, Varnum et al., 2017), endosomes (Raha et al., 2017) 
and exocytic vesicles (Prada et al., 2006). TREM2 undergoes maturation by N-linked 
glycosylation during this transport process (Park et al., 2015), however the biological relevance 
of these modifications remains unknown. Full-length membrane bound TREM2 undergoes 
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proteolytic processing by a disintegrin and metalloproteinases (ADAM) α-secretases,  
ADAM10 or ADAM17, which results in ectodomain shedding between H157 and S158 
residues generating a soluble form of TREM2 (sTREM2) (Figure 1.6) (Feuerbach et al., 2017, 
Kleinberger et al., 2014, Schlepckow et al., 2017, Thornton et al., 2017, Wunderlich et al., 
2013). This cleavage terminates TREM2 signalling and its downstream effector functions. 
Interestingly, p.H157Y was recently identified as an AD risk variant (Jiang et al., 2016), and 
shows increased sTREM2 levels, reduced cell surface TREM2 as well as impaired 
phagocytosis in vitro (Schlepckow et al., 2017). 
 
Figure 1.6 TREM2/DAP12 signalling. (A) TREM2 binds to several ligands, and signals through its 
Ig-like V-type domain. The positively charged conserved lysine residue on TREM2 transmembrane 
region (amino acid 186) electrostatically interacts with negatively charged aspartic acid residue in 
DNAX-activating protein of 12 kDa (DAP12). Src kinase phosphorylates the DAP12 
immunoreceptor tyrosine-based activation motifs (ITAM). This phosphorylation recruits and 
activates spleen tyrosine kinase (Syk), which triggers downstream effectors including extracellular 
signal-regulated kinases (ERK), phosphoinositide 3-kinase (PI3K), phospholipase C-γ (PLCγ) and Vav. 
Subsequent intracellular Ca2+ efflux and actin cytoskeletal reorganisation promotes microglial functions 
such as motility and phagocytosis. TREM2 undergoes sequential proteolytic processing by ADAM 10 
or 17 resulting in ectodomain shedding of sTREM2. The remaining TREM2 transmembrane domain is 
subsequently cleaved by γ-secretase, releasing a C-terminal fragment (CTF) (Glebov et al., 2016, 
Wunderlich et al., 2013). TREM2 cleavage by ADAMs terminates the downstream signalling cascade. 
(B) The receptor for sTREM2 is unknown. The ectodomain shedding appears to activate PI3K, ERK 
and nuclear factor (NF)-κB pathways and enhances several microglial functions related to phagocytosis. 
(Adapted from (Konishi and Kiyama, 2018)). 
sTREM2 is readily found in in biological fluids such as serum and CSF in both mice and 
humans (Henjum et al., 2016, Kleinberger et al., 2017, Kleinberger et al., 2014, Wunderlich et 
al., 2013). CSF sTREM2 levels are thought to reflect the degree of microglial activation in the 
brain during disease progression (Heslegrave et al., 2016, Piccio et al., 2016) as well as the 
severity of brain atrophy due to its association with neuronal injury markers (Suarez-Calvet et 
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al., 2016b). Interestingly, CSF sTREM2 levels peak specifically during the early symptomatic 
stages of AD (Suarez-Calvet et al., 2016a), suggesting that sTREM2 may be a biomarker for 
not only disease severity but also cognitive decline that manifests in the earlier stages of AD 
(Jiang et al., 2014).  
3.1 TREM2/DAP12 and Nasu Hakola disease 
DAP12 belongs to the type 1 transmembrane adapter protein family (Wilson et al., 2000). It is 
abundantly expressed on immune cells such as natural killer cells, myeloid cells and 
neutrophils, and forms an ITAM-containing disulphide-linked homodimer (Figure 1.6). 
DAP12 itself is thought to have no ligand-binding capability due to its short extracellular 
domain (Lanier, 2009). To initiate an intracellular signalling cascade, TREM2 interacts with 
DAP12 within the transmembrane region through an electrostatic association (Bouchon et al., 
2000), which triggers a downstream signalling event regulating cell migration and survival, 
phagocytosis or cytokines release (Figure 1.6) (Colonna et al., 2007). Homozygous loss-of-
function mutation in TREM2 or DAP12 leads to a rare neurodegenerative disease associated 
with leukodystrophy, osteoporosis and a presenile form of frontal lobe dementia called Nasu 
Hakola disease (NHD, also known as polycystic lipomembranous osteodysplasia with 
sclerosing leukoencephalopathy, PLOSL) (Klunemann et al., 2005, Paloneva et al., 2001, 
Paloneva et al., 2002). To date, 11 TREM2 mutations have been reported to cause NHD, some 
of which include p.W78X, p.W44X, p.K186N, and p.D134G (Paloneva et al., 2002). 
Additionally, amyloid PET imaging revealed extensive Aβ pathology in a patient carrying the 
p.Q33X TREM2 variant (Ghezzi et al., 2017), which is more commonly found in FTD patients 
(Guerreiro et al., 2013b). Moreover, NHD patients develop bone cysts as early as the second 
decade of life, with dementia manifesting due to atrophy of the corpus callosum and frontal 
lobe regions. Other pathological changes include loss of myelin, gliosis, and enlarged brain 
ventricles, which also affect motor functions. As a result, NHD patients perish as early as the 
late fourth decade of life. Currently there are no NHD mouse models available, however 
Trem2- or Dap12-deficient mice display similar phenotypes including impaired myelination, 
reduced amyloid plaque-associated microglia and increased accumulation of diffuse Aβ 
plaques (Mazaheri et al., 2017, Wang et al., 2015, Keren-Shaul et al., 2017, Wang et al., 2016, 
Yuan et al., 2016, Parhizkar et al., 2019, Cantoni et al., 2015, Piccio et al., 2007, Kaifu et al., 
2003, Nataf et al., 2005). Moreover, TREM2 expression appears to be severely downregulated 
in dendritic cells from NHD patients, suggesting that disrupted TREM2 expression or 
signalling may be responsible for NHD symptoms.  
3.2 TREM2 and FTD 
Heterozygous or homozygous TREM2 coding variants such as p.T66M (Guerreiro et al., 
2013b, Le Ber et al., 2014), p.W198X (Giraldo et al., 2013), p.Q33X and p.Y38C (Guerreiro 
et al., 2013b) are associated with FTD. Although the p.T66M and p.Y38C heterozygous 
variants are found in AD patients, they are more commonly associated with FTD (Guerreiro et 
al., 2013b, Jonsson and Stefansson, 2013). Other AD-associated TREM2 variants such as 
p.T96K, p.L211P and p.R47H also increase the risk of developing FTD (Thelen et al., 2014, 
Rayaprolu et al., 2013). The p.T66M and p.Y38C mutations that reside in the Ig-like domain 
are misfolded in the ER (Kober et al., 2016, Park et al., 2015) and show impaired cell surface 
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trafficking (Kleinberger et al., 2014, Song et al., 2017), which may explain how TREM2 loss-
of-function affects FTD-like syndrome (Guerreiro et al., 2013b). Additionally, the 
glycosylation pattern of these mutations is also affected indicating impairment in maturation 
that could affect TREM2 function (Park et al., 2015).  
Knocking in p.T66M missense mutation in mice showed a gene dose-dependent reduction in 
sTrem2 in the brain, serum, and CSF due to ER retention of mutant immature sTrem2 
(Kleinberger et al., 2017). Decreased cell surface Trem2 resulted in loss of Trem2 function as 
observed by a decline in phagocytic ability of bone marrow-derived macrophages as well as 
reduction in TSPO and fluorodeoxyglucose (FDG) PET, which are indicative of decreased 
inflammation and impaired brain glucose metabolism or cerebral blood flow respectively. 
Interestingly, the p.T66M knock-in model also revealed evidence of poor removal of myelin 
debris with aging as observed by increased microglial nodules throughout the brain 
(Kleinberger et al., 2017). Although no bone-related pathology was observed in these mice, 
the model may help address several important questions such as how cerebral blood flow 
affects TREM2 maturation and whether sTREM2 or full length TREM2 may influence 
hypometabolism and neuronal activity in the brain in a cell-autonomous manner. Moreover, it 
may serve as an essential loss of Trem2 function model, which may be more suitable for 
comparing the clinical situation than manipulating gene expression, as is currently typical. 
3.3 TREM2 and AD 
Although TREM2 variants are rare with allele frequencies below 1%, several heterozygous 
TREM2 variants are found to confer higher AD risk including p.R47H, p.R62H, p.D87N, 
p.H157Y, p.T96K, p.W191X, p.L211P and R136Q (Bonham et al., 2017, Guerreiro et al., 
2013a, Jiang et al., 2016, Jin et al., 2014, Jin et al., 2015, Jonsson et al., 2013). The TREM2 
variants include early stop sites and ectodomain mutations, which consequently produce 
partially or non-functional protein (Giraldo et al., 2013). The p.R47H variant found more 
commonly in European and North American populations increases the risk of LOAD by 
approximately 3-fold, with similar odds ratio to single APOE ε4 allele (Guerreiro and Hardy, 
2013, Lill et al., 2015). Additionally, it is associated with higher total tau and phosphorylated 
tau in CSF (Cruchaga et al., 2013). The p.R47H variant has since then been confirmed to be 
associated with both early onset AD and LOAD in various case populations independent of the 
APOE ε4 risk variant (Jin et al., 2014, Pottier et al., 2013, Ruiz et al., 2014, Sims et al., 2017). 
LOAD patients with the p.R47H variant present an earlier onset of disease symptoms including 
faster cognitive decline (Slattery et al., 2014, Del-Aguila et al., 2018).  
While NHD-associated TREM2 variants impact protein expression, stability, folding and 
transport, the AD-associated TREM2 variants seem to impact the efficiency of TREM2 
signalling (Kleinberger et al., 2014, Ma et al., 2016, Song et al., 2016, Kober et al., 2016). 
Moreover, p.R47H variant AD patients show impaired microglial clustering around plaques 
(Yuan et al., 2016, Parhizkar et al., 2019), resulting in larger, more diffuse plaques (Yuan et 
al., 2016). Reduced plaque-surrounding microglia was also recently reported in 5xFAD mice 
overexpressing human p.R47H TREM2 but lacking endogenous expression of murine Trem2 
(Song et al., 2018). The microglial pathology the p.R47H mice were comparable to Trem2-
deficient 5xFAD mice, suggesting that the mutation causes a loss-of-function (Song et al., 
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2018). Murine p.R47H Trem2 knock-in also confirmed loss-of-function effects as a result of 
reduced Trem2 mRNA and protein production (Cheng-Hathaway et al., 2018). However, 
Trem2 haploinsufficieny appeared to be an artefact introduced by CRISPR resulting in atypical 
splicing of exon 1 and 2 in the p.R47H murine mutation, which was otherwise not observed in 
humans carrying the p.R47H coding variant (Xiang et al., 2018). These findings highlight the 
need to determine how different TREM2 variants influence alternative splicing and their 
functional consequences.  
3.3.1 TREM2, microglia function and Aβ pathology 
Microglia play an active role in regulating amyloid pathology by phagocytosis. However, the 
inconsistent results from microglia depletion studies using APP transgenic mice raise a critical 
question: At which disease stage does microglia most efficiently restrain amyloidogeneisis? 
Microglia depletion in vivo has shown that the timing and duration of microglia interaction 
with amyloid pathology plays an important role in its phagocytic abilities. Herpes simplex virus 
thymidine kinase (HSTK) is also known as a suicide gene as it converts ganciclovir (GCV) 
into toxic DNA replication inhibitors that results in cell death (Czako and Marton, 1994). Thus, 
expressing HSTK on a CD11b promoter, which is expressed in macrophages and microglia, 
results in microglia depletion upon GCV treatment in APPPS1 mice crossed with HSTK-
expressing mice (Grathwohl et al., 2009). Similarly, treating 5xFAD mice with macrophage 
colony stimulating factor 1 receptor (CSFR1) inhibitor results in microglia depletion 
(Spangenberg et al., 2016). Both microglia depletion systems do not affect plaque burden after 
onset of Aβ pathology (Spangenberg et al., 2016, Grathwohl et al., 2009). However, depleting 
microglia by CSFR1 inhibition prior to Aβ deposition dramatically reduced plaque pathology 
in 5xFAD mice (Sosna et al., 2018), suggesting that microglia may be involved in the initial 
seeding stage of plaque formation. Thus by eliminating newly seeded plaques, Trem2 may 
have protective functions at least early during amyloidogenesis (Parhizkar et al., 2019). 
A protective function of TREM2 is also supported by disease-associated TREM2 variants 
causing a loss-of-function (Abud et al., 2017, Kleinberger et al., 2017, Kleinberger et al., 2014, 
Song et al., 2018, Yeh et al., 2016). Trem2 haploinsufficiency or total genetic ablation reduces 
plaque-associated microglia (Jay et al., 2015, Wang et al., 2015, Ulrich et al., 2014), suggesting 
that Trem2 signalling is required to activate and recruit microglia to the plaques. Additionally, 
transcriptomic analyses of plaque-surrounding microglia show major changes in their 
molecular markers related to chemotaxis, proliferation, response to wounding and locomotion, 
compared to microglia that retain a homeostatic profile when no plaques are present 
(Krasemann et al., 2017, Mazaheri et al., 2017). Thus, Trem2-expressing microglia appear to 
be essential for promoting microglial association to plaques and constitutes a major population 
of DAM in Aβ-depositing mouse models (Keren-Shaul et al., 2017, Krasemann et al., 2017). 
Impaired microglial clustering around plaques have also been reported in AD cases with 
different TREM2 variants (Parhizkar et al., 2019, Yuan et al., 2016). Additionally, loss of 
Trem2 function shows increased seeding of early plaque deposits, most likely due to impaired 
Aβ clearance by microglia (Parhizkar et al., 2019). The inability of microglia to cluster around 
Aβ results in enlarged and more diffused plaques, which appear as star-shaped fibrils (Yuan et 
al., 2016, Wang et al., 2016). Such changes in plaque morphology as well as neuritic plaques 
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were also observed in AD patients carrying the p.R47H variant, similar to that observed in 
Trem2-deficient mice (Yuan et al., 2016). Earlier studies reported inconsistent results about 
the effect of TREM2 on amyloid plaque pathology (Jay et al., 2015, Ulrich et al., 2014, Wang 
et al., 2015), although it was later identified to be an age- and disease progression-dependent 
effect (Jay et al., 2017, Parhizkar et al., 2019). Moreover, Trem2 upregulation increases the 
phagocytic ability of plaque-surrounding microglia as indicated by plaque-derived material 
found in the DAM population (Keren-Shaul et al., 2017, Yuan et al., 2016, Parhizkar et al., 
2019).  
Recently, Zhong and colleagues reported a protective function of sTREM2 in Aβ-depositing 
mice (Zhong et al., 2019). They demonstrated that similarly to full-length Trem2, sTREM2 
reduced plaque deposition and associated dystrophic neurites by enhancing microglial 
proliferation, migration and clustering around plaques as well as lysosomal degradation of Aβ. 
Additionally, sTREM2 rescued long-term potentiation and memory deficits, which are 
otherwise impaired by Aβ plaque deposition in 5xFAD mice. All effects were attenuated 
following microglia depletion, suggesting that sTREM2 mediates its protective effects 
primarily through microglia and that microglia are central to modifying synaptic plasticity and 
amyloidogenesis. Thus, the CSF sTREM2 increase observed at the prodromal mild cognitive 
impairment stage of AD patients (Suarez-Calvet et al., 2016b) may represent a protective 
response to the initial threat caused by Aβ plaques that likely drive the pathogenic cascades of 
AD (Hardy and Higgins, 1992, Hardy and Selkoe, 2002). The functional similarities between 
sTrem2 and Trem2 may pose a challenge for therapeutic modulation of TREM2. This is 
because while blocking ADAM-mediated cleavage may enhance the protective functions of 
TREM2 due to increase signalling, reducing sTrem2 may present detrimental side effects that 
would be difficult to predict, especially since a receptor for sTrem2 has not yet been identified. 
4. ApoE – Structure and function 
ApoE is highly induced in DAM similarly to Trem2 (Keren-Shaul et al., 2017, Krasemann et 
al., 2017). Under healthy physiological conditions, the 299 amino acid glycoprotein is highly 
expressed in the liver, and in the brain, primarily by astrocytes (Zhang et al., 2014, Zhang et 
al., 2016), as well as microglia and damaged neurons to a lesser extent (Xu et al., 2006). ApoE 
is mainly known as a major cholesterol carrier in the brain that maintains the structure of 
specific lipoproteins (Kim et al., 2009a). Native ApoE is primarily lipidated by Adenosine 
triphosphate-binding cassette transporter A1 (ABCA1) in the brain. Additionally, ApoE 
facilitates transport of lipids among different cell types by serving as a ligand for the LDL 
receptor (LDLR) family and lipoprotein receptor-related protein (LRP) (Kim et al., 2009a) 
(Figure 1.7). 
Compared to humans that express three major isoforms of ApoE, with ApoE3 being the most 
predominant isoform, mice express only one type of ApoE protein (Kim et al., 2009a). The 
human ApoE include two separate N- and C-terminal domains joined by a flexible hinge. The 
N-terminus includes the receptor binding regions, which differs in the ApoE isoform residues 
(ApoE4, arginine 112; ApoE3 and ApoE2, cysteine 112). The C-terminal domain contains the 
lipid-binding region (residues 244-272) (Bu, 2009). The cysteine residue at 112 found in both 
ApoE2 and ApoE3 may form disulphide-linked dimers, whereas the arginine residue in ApoE4 
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significantly impedes lipid binding (Weisgraber, 1990, Weisgraber and Shinto, 1991). 
Additionally, while ApoE3 and ApoE4 that have arginine at residue 158 display normal 
receptor binding activity, ApoE2 with cysteine shows impaired receptor binding abilities and 
is associated with the recessive form of type III hyperlipoproteinemia (Ahn et al., 2009, 
Weisgraber et al., 1990, Weisgraber et al., 1994, Weisgraber and Shinto, 1991). This suggests 
that the differences in one or two amino acids in the N- and C-terminal domains significantly 
alter their interaction and preference to bind lipid and receptor proteins involved in cholesterol 
uptake (Mahley and Huang, 2012). To date, it is not clear how the function of ApoE as a lipid 
redistributor is mechanistically related to several diseases including AD, Down’s syndrome-
associated dementia and CAA. However, the ε4 allele disease risk association suggests that 
ApoE might contribute to these diseases by influencing synaptic plasticity, tau 
hyperphosphorylation, impairments in BBB integrity, neuroinflammation, as well as Aβ 
aggregation and clearance (Holtzman and Fagan, 1998, Kim et al., 2009a, Mahley and Huang, 
2012). 
4.1 ApoE and Aβ pathology  
ApoE was found to be a constituent of amyloid plaques (Corder et al., 1993, Strittmatter et al., 
1993b) with a positive correlation between copies of APOE ε4 alleles and senile plaque density 
(Rebeck et al., 1993, Schmechel et al., 1993). The APOE ε4 gene dosage has also been closely 
linked to fibrillar Aβ and low Aβ42 levels in CSF (Morris et al., 2010, Sunderland et al., 2004). 
Earlier studies on ApoE often produced inconsistent findings as it was later found that the 
affinity for ApoE to bind to Aβ highly depended on the lipidation state of ApoE, the Aβ species, 
as well as the pH levels of the in vitro model system (LaDu et al., 1994, Sanan et al., 1994, 
Strittmatter et al., 1993a). The isoform-dependent effects on Aβ aggregation was better 
understood using transgenic mice expressing human ApoE alleles crossed with APP transgenic 
models. For example, while Aβ burden was significantly reduced in ApoE-null PDAPP mice 
(Bales et al., 1999), mice lacking endogenous ApoE but expressing ε3 or ε4 isoform displayed 
less Aβ deposition compared to mice expressing endogenous ApoE. These findings suggest 
that human ApoE influences Aβ clearance (Holtzman et al., 2000). It is not yet known how 
exactly ApoE interacts with Aβ and influences its clearance, though several mechanisms have 
been proposed including, enzymatic degradation (Jiang et al., 2008), cellular uptake (Thal et 
al., 2000, Yeh et al., 2016, Ulrich et al., 2018), interaction with receptors and transporters on 
cell surface (Verghese et al., 2013), transport across the BBB (Cirrito et al., 2005), and ISF-
CSF flow (Castellano et al., 2011, Cirrito et al., 2003). ApoE4-expressing PDAPP mice display 
higher ISF Aβ levels with a slower Aβ clearance rate compared to ApoE3 mice. In comparison, 
ApoE2-expressing mice show lowest ISF Aβ and fastest Aβ clearance (Cirrito et al., 2003). 
Additionally, immunotherapy studies using anti-ApoE antibody in amyloid plaque-bearing 
mouse models have shown to reduce Aβ plaque burden in an antibody dose-dependent manner 
(Liao et al., 2014, Kim et al., 2012). Targeting ApoE with anti-sense oligonucleotides from 
birth also appeared to reduce Aβ plaque pathology; however, the effect was lost if the treatment 




Figure 1.7 ApoE production, lipidation and its interaction with Aβ. Under stress or inflammation, 
ApoE is produced by astrocytes and DAM, and to a lesser extent in neurons. ApoE is lipidated in the 
astrocytes by ABCA1 and secreted into the interstitial fluid. The process begins once sufficient 
phospholipids and cholesterol bind to ABCA1, which triggers a conformational change leading to its 
dimerisation. The lipidated dimers immobilise actin filaments on the plasma membrane until lipid-free 
ApoE directly binds to the ABCA1 dimer. Upon binding, ApoE is lipidated by ABCA1 and leaves the 
dimer, which once again dissociates into a monomer to begin the process again. ApoE-containing 
lipoprotein particles are endocytosed into other cells via LDLR and LRP, the major metabolic receptors 
for ApoE. Amyloidogenic APP processing leads to Aβ production and release from neurons into the 
interstitial fluid (ISF). ApoE may bind to monomeric and smaller oligomeric soluble Aβ species and 
facilitate its aggregation into Aβ plaques in an isoform-dependent manner. However, ApoE could also 
bind to Aβ to facilitate its uptake and clearance through microglia in a TREM2-dependent manner or 
across the BBB. Accordingly, ApoE may bind to TREM2 to promote a DAM profile and enhance 
phagocytic uptake of Aβ. 
More recent studies suggest that ApoE interacts with Aβ to affect its fibrillogenesis (Liu et al., 
2017) in an isoform dependent manner (Castellano et al., 2011, Fitz et al., 2012). While ApoE 
is largely lipidated in the brain, altering the ApoE lipidation state has a profound impact on Aβ 
fibrillization and inflammation. For example, LDLR-deficient 5xFAD mice displayed 
increased thioflavine S-positive fibrillar plaque burden compared to 5xFAD controls, with 
reduced microgliosis and astrogliosis (Katsouri and Georgopoulos, 2011). Similar results have 
been reported in Tg2576 transgenic mice lacking LDLR expression (Cao et al., 2006). In 
support of these findings, overexpression of LDLR in APPPS1 mice reduced endogenous 
ApoE levels and inhibited Aβ deposition, as well as increased Aβ clearance (Kim et al., 2009b). 
Furthermore, the intronic microRNA-33 supresses ABCA1 expression through translational 
repression or by inducing mRNA decay (Koldamova et al., 2005, Rayner et al., 2010). Thus, 
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ablating microRNA-33 expression significantly increased ABCA1 levels and ApoE lipidation, 
which in turn reduced Aβ levels in the brain (Kim et al., 2015). Similarly, overexpression of 
ABCA1 has shown to increase ApoE lipidation with a corresponding decrease in Aβ deposition 
in PDAPP mice (Wahrle et al., 2008). Whereas ABCA1 deficiency reduces ApoE levels in the 
brain and consequently elevates Aβ deposition in APP23 mice (Koldamova et al., 2005). 
4.1.1 TREM2-APOE modulation of Aβ pathology 
The effects of APOE on immune activation have largely focused on astroglia due to their 
significant contribution to modulation of synaptic activity, inflammation and regulation of the 
BBB. As nascent ApoE is primarily lipidated by ABCA1, which is heavily expressed in 
astrocytes in mice (Zhang et al., 2014, Zhang et al., 2016), studies on loss of ApoE function in 
the brain parenchyma or the BBB were mainly focused on astroglia (Funato et al., 1998, Thal 
et al., 2000, Koistinaho et al., 2004). Earlier studies indicated that ApoE affects receptor-
mediated phagocytosis by microglia (Paresce et al., 1997, Paresce et al., 1996, Uchihara et al., 
1995). However, most of these studies were performed in vitro, which may have heavily 
influenced the microglial signature, and therefore function (Butovsky and Weiner, 2018). Until 
recently, not much was known about the impact of loss of ApoE function on microgliosis. 
Interestingly, similar to Trem2 knockout mice (Wang et al., 2016, Yuan et al., 2016), ApoE-
deficient APPPS1-21 or APP/PS1de9 displayed impaired microglial clustering around Aβ 
plaques, which appeared enlarged with star-shaped fibrils (Ulrich et al., 2018). Furthermore, 
ApoE isoforms appear to have differential effects on microglial clustering around plaques, with 
ApoE4 displaying increased number of microglia around plaques compared to ApoE3 in mice 
(Rodriguez et al., 2014) but not in AD patients (Serrano-Pozo et al., 2013). Additionally, loss 
of Trem2 function mice display reduced ApoE/Aβ colocalisation with significantly decreased 
microglial ApoE compared to astroglial ApoE levels (Parhizkar et al., 2019). With recent 
developments in transcriptomic analysis, we now know that microglia also express genes 
required for ApoE production or lipidation, such as ABCA1 (Zhang et al., 2014, Zhang et al., 
2016). This suggests that along with ApoE secreted by astroglia, ApoE of microglial origin 
may have a profound effect on its phagocytic ability to modulate plaque pathology by 
influencing its aggregation and/or clearance. Thus, TREM2 and APOE may share similar 
mechanisms involving LOAD pathogenesis as a result of changes in microglial pathology 
(Krasemann et al., 2017). For example, TREM2 may bind to ApoE accumulated on the surfaces 
of damaged or dead neurons, which may enhance opsonisation and promote neuronal 
phagocytosis by microglia. However, the exact mechanism through which the interaction 





II. Aim of the study 
Microglia are considered one of the key players in maintaining brain homeostasis through 
phagocytic removal of harmful pathogens such as Aβ plaques. In fact, microgliosis is one of 
the key pathological hallmarks of AD and other neurodegenerative diseases, as loss of 
microglial function is believed to be crucial in determining the outcome and progression of 
LOAD. This is supported by the recent GWAS reporting that more than half of AD risk genes 
are implicated in microglial and innate immune cell function, including the two top risk genes 
APOE and TREM2. The APOE ε4 allele is long known to be the strongest genetic risk factor 
for AD due to its pro-aggregating effects on Aβ as well as impaired plaque clearance. Both 
APOE and TREM2 mRNA expression are upregulated in microglia clustering around plaques 
and TREM2 deficiency is consistently reported to reduce the number of microglia around 
plaques. However, the functional role of TREM2 in amyloid metabolism remains controversial 
due to conflicting results from different transgenic model systems studied at different stages of 
Aβ pathology. Furthermore, it remains unclear whether these results from mouse models 
translate to human AD pathology. As Aβ accumulation and deposition in the brain likely drives 
the pathogenic cascade of AD, the major goal of my PhD thesis was to provide a critical link 
between Aβ metabolism and TREM2-dependent microglial response in the pathogenesis of 
AD. 
Do disease-associated TREM2 variants confer a loss-of-function? How does the FTD-
associated p.T66M variant impact microglial function in vivo? 
When I started my PhD, all functional studies on TREM2 were published using Trem2 
knockout mice, however very little was reported on the functional effects of disease-associated 
TREM2 variants. Therefore, I collaborated with Gernot Kleinberger and colleagues to 
characterise a mouse model expressing the FTD-like syndrome-associated Trem2 p.T66M 
mutation at an endogenous level. This variant has not been linked to AD, such as the p.R47H 
variant. However, in comparison, the p.T66M mutation displays stronger TREM2 loss-of-
function effects on TREM2 maturation, shedding and phagocytic uptake in vitro. Thus, to 
understand its functional consequences on microglia in vivo, I collected brain, cerebrospinal 
fluid and serum samples from WT, heterozygous and homozygous p.T66M-expressing mice 
of different ages. 
What is the factor connecting amyloidogenesis and microglial phagocytosis? How does 
the TREM2-Aβ interaction fit in the amyloid cascade hypothesis? 
To investigate a potential interaction between TREM2 and Aβ pathology, I used the amyloid 
seeding paradigm and analysed Trem2-dependent effects on early Aβ plaque formation as well 
as associated microgliosis in APPPS1 mice. For this, I included both APPPS1/Trem2-/- and 
APPPS1/Trem2p.T66M mice as loss of Trem2 function models. I extended the analyses to study 
changes in amyloidogenesis and microglial activity with aging in APPPS1 mice, which were 
not exogenously seeded. Lastly, I examined whether loss of Trem2 immunomodulatory 
functions can be linked to Aβ metabolism through changes in APOE and whether these 




Abud EM, Ramirez RN, Martinez ES, Healy LM, Nguyen CHH, Newman SA, Yeromin AV, Scarfone 
VM, Marsh SE, Fimbres C, Caraway CA, Fote GM, Madany AM, Agrawal A, Kayed R, Gylys KH, 
Cahalan MD, Cummings BJ, Antel JP, Mortazavi A, Carson MJ, Poon WW and Blurton-Jones M 
(2017) 'iPSC-Derived Human Microglia-like Cells to Study Neurological Diseases', Neuron, 94(2), pp. 
278-293 e9. 
Aguzzi A, Heikenwalder M and Polymenidou M (2007) 'Insights into prion strains and neurotoxicity', 
Nat Rev Mol Cell Biol, 8(7), pp. 552-61. 
Ahn K, Song JH, Kim DK, Park MH, Jo SA and Koh YH (2009) 'Ubc9 gene polymorphisms and late-
onset Alzheimer's disease in the Korean population: a genetic association study', Neurosci Lett, 465(3), 
pp. 272-5. 
Alzheimer A (1907) 'Über eine eigenartige Erkrankung der Hirnrinde', Allg Zschr Psychiatr Psych 
gerichtl Med. , 64, pp. 146–148. 
Arriagada PV, Growdon JH, Hedley-Whyte ET and Hyman BT (1992) 'Neurofibrillary tangles but not 
senile plaques parallel duration and severity of Alzheimer's disease', Neurology, 42(3 Pt 1), pp. 631-9. 
Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, Wolozin B, Butovsky O, Kugler S and 
Ikezu T (2015) 'Depletion of microglia and inhibition of exosome synthesis halt tau propagation', Nat 
Neurosci, 18(11), pp. 1584-93. 
Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H, Li X, Rademakers R, Kang SS, Xu H, 
Younkin S, Das P, Fryer JD and Bu G (2015) 'Apolipoprotein E Is a Ligand for Triggering Receptor 
Expressed on Myeloid Cells 2 (TREM2)', J Biol Chem, 290(43), pp. 26043-50. 
Bachhuber T, Katzmarski N, McCarter JF, Loreth D, Tahirovic S, Kamp F, Abou-Ajram C, Nuscher 
B, Serrano-Pozo A, Muller A, Prinz M, Steiner H, Hyman BT, Haass C and Meyer-Luehmann M (2015) 
'Inhibition of amyloid-beta plaque formation by alpha-synuclein', Nat Med, 21(7), pp. 802-7. 
Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M, Eninger T, Lambert 
M, Pilotto A, Shimshek DR, Neumann U, Kahle PJ, Staufenbiel M, Neumann M, Maetzler W, Kuhle J 
and Jucker M (2016) 'Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression 
in Mouse Models and in Neurodegenerative Diseases', Neuron, 91(2), pp. 494-496. 
Bailey CC, DeVaux LB and Farzan M (2015) 'The Triggering Receptor Expressed on Myeloid Cells 2 
Binds Apolipoprotein E', J Biol Chem, 290(43), pp. 26033-42. 
Baker HF, Ridley RM, Duchen LW, Crow TJ and Bruton CJ (1993) 'Evidence for the experimental 
transmission of cerebral beta-amyloidosis to primates', Int J Exp Pathol, 74(5), pp. 441-54. 
Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, 
Petegnief V, Ghetti B and Paul SM (1999) 'Apolipoprotein E is essential for amyloid deposition in the 
APP(V717F) transgenic mouse model of Alzheimer's disease', Proc Natl Acad Sci U S A, 96(26), pp. 
15233-8. 
Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC and Wilson RS (2006) 
'Neuropathology of older persons without cognitive impairment from two community-based studies', 
Neurology, 66(12), pp. 1837-44. 
 
38 
Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J, Esselmann H and De Strooper B 
(2006) 'Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms', J 
Neurochem, 96(3), pp. 732-42. 
Bolmont T, Clavaguera F, Meyer-Luehmann M, Herzig MC, Radde R, Staufenbiel M, Lewis J, Hutton 
M, Tolnay M and Jucker M (2007) 'Induction of tau pathology by intracerebral infusion of amyloid-
beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice', Am J 
Pathol, 171(6), pp. 2012-20. 
Bonham LW, Sirkis DW, Fan J, Aparicio RE, Tse M, Ramos EM, Wang Q, Coppola G, Rosen HJ, 
Miller BL and Yokoyama JS (2017) 'Identification of a rare coding variant in TREM2 in a Chinese 
individual with Alzheimer's disease', Neurocase, 23(1), pp. 65-69. 
Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG, Price DL and 
Sisodia SS (1997) 'Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant 
presenilin 1 and amyloid precursor proteins', Neuron, 19(4), pp. 939-45. 
Bouchon A, Dietrich J and Colonna M (2000) 'Cutting edge: inflammatory responses can be triggered 
by TREM-1, a novel receptor expressed on neutrophils and monocytes', J Immunol, 164(10), pp. 4991-
5. 
Bouchon A, Hernandez-Munain C, Cella M and Colonna M (2001) 'A DAP12-mediated pathway 
regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells', J Exp Med, 
194(8), pp. 1111-22. 
Braak H and Del Tredici K (2011) 'Alzheimer's pathogenesis: is there neuron-to-neuron propagation?', 
Acta Neuropathol, 121(5), pp. 589-95. 
Brawek B, Schwendele B, Riester K, Kohsaka S, Lerdkrai C, Liang Y and Garaschuk O (2014) 
'Impairment of in vivo calcium signaling in amyloid plaque-associated microglia', Acta Neuropathol, 
127(4), pp. 495-505. 
Brendel M, Kleinberger G, Probst F, Jaworska A, Overhoff F, Blume T, Albert NL, Carlsen J, Lindner 
S, Gildehaus FJ, Ozmen L, Suárez-Calvet M, Bartenstein P, Baumann K, Ewers M, Herms J, Haass C 
and Rominger A (2017) 'Increase of TREM2 during Aging of an Alzheimer’s Disease Mouse Model Is 
Paralleled by Microglial Activation and Amyloidosis', Frontiers in Aging Neuroscience, 9. 
Bu G (2009) 'Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and 
therapy', Nat Rev Neurosci, 10(5), pp. 333-44. 
Butovsky O, Jedrychowski MP, Moore CS, Cialic R, Lanser AJ, Gabriely G, Koeglsperger T, Dake B, 
Wu PM, Doykan CE, Fanek Z, Liu L, Chen Z, Rothstein JD, Ransohoff RM, Gygi SP, Antel JP and 
Weiner HL (2014) 'Identification of a unique TGF-beta-dependent molecular and functional signature 
in microglia', Nat Neurosci, 17(1), pp. 131-43. 
Butovsky O and Weiner HL (2018) 'Microglial signatures and their role in health and disease', Nat Rev 
Neurosci, 19(10), pp. 622-635. 
Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, Thomas-Anterion C, Michon 
A, Martin C, Charbonnier F, Raux G, Camuzat A, Penet C, Mesnage V, Martinez M, Clerget-Darpoux 
F, Brice A and Frebourg T (1999) 'Early-onset autosomal dominant Alzheimer disease: prevalence, 
genetic heterogeneity, and mutation spectrum', Am J Hum Genet, 65(3), pp. 664-70. 
Cannon JP, O'Driscoll M and Litman GW (2012) 'Specific lipid recognition is a general feature of 
CD300 and TREM molecules', Immunogenetics, 64(1), pp. 39-47. 
 
39 
Cantoni C, Bollman B, Licastro D, Xie M, Mikesell R, Schmidt R, Yuede CM, Galimberti D, 
Olivecrona G, Klein RS, Cross AH, Otero K and Piccio L (2015) 'TREM2 regulates microglial cell 
activation in response to demyelination in vivo', Acta Neuropathol, 129(3), pp. 429-47. 
Cao D, Fukuchi K, Wan H, Kim H and Li L (2006) 'Lack of LDL receptor aggravates learning deficits 
and amyloid deposits in Alzheimer transgenic mice', Neurobiol Aging, 27(11), pp. 1632-43. 
Carson JA and Turner AJ (2002) 'Beta-amyloid catabolism: roles for neprilysin (NEP) and other 
metallopeptidases?', J Neurochem, 81(1), pp. 1-8. 
Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, 
Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ and Holtzman DM (2011) 
'Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance', Sci Transl Med, 
3(89), pp. 89ra57. 
Caughey B, Baron GS, Chesebro B and Jeffrey M (2009) 'Getting a grip on prions: oligomers, amyloids, 
and pathological membrane interactions', Annu Rev Biochem, 78, pp. 177-204. 
Cella M, Buonsanti C, Strader C, Kondo T, Salmaggi A and Colonna M (2003) 'Impaired differentiation 
of osteoclasts in TREM-2-deficient individuals', J Exp Med, 198(4), pp. 645-51. 
Cheng-Hathaway PJ, Reed-Geaghan EG, Jay TR, Casali BT, Bemiller SM, Puntambekar SS, von 
Saucken VE, Williams RY, Karlo JC, Moutinho M, Xu G, Ransohoff RM, Lamb BT and Landreth GE 
(2018) 'The Trem2 R47H variant confers loss-of-function-like phenotypes in Alzheimer's disease', Mol 
Neurodegener, 13(1), pp. 29. 
Chertoff M, Shrivastava K, Gonzalez B, Acarin L and Gimenez-Llort L (2013) 'Differential modulation 
of TREM2 protein during postnatal brain development in mice', PLoS One, 8(8), pp. e72083. 
Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J, Strome R, Zuker N, Loukides J, 
French J, Turner S, Lozza G, Grilli M, Kunicki S, Morissette C, Paquette J, Gervais F, Bergeron C, 
Fraser PE, Carlson GA, George-Hyslop PS and Westaway D (2001) 'Early-onset amyloid deposition 
and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 
695', J Biol Chem, 276(24), pp. 21562-70. 
Chui DH, Tanahashi H, Ozawa K, Ikeda S, Checler F, Ueda O, Suzuki H, Araki W, Inoue H, Shirotani 
K, Takahashi K, Gallyas F and Tabira T (1999) 'Transgenic mice with Alzheimer presenilin 1 mutations 
show accelerated neurodegeneration without amyloid plaque formation', Nat Med, 5(5), pp. 560-4. 
Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, 
Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D and Holtzman DM (2005) 'P-glycoprotein 
deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse 
model', J Clin Invest, 115(11), pp. 3285-90. 
Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales 
KR, Paul SM, DeMattos RB and Holtzman DM (2003) 'In vivo assessment of brain interstitial fluid 
with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life', J 
Neurosci, 23(26), pp. 8844-53. 
Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I 
and Selkoe DJ (1992) 'Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease 
increases beta-protein production', Nature, 360(6405), pp. 672-4. 
 
40 
Clavaguera F, Akatsu H, Fraser G, Crowther RA, Frank S, Hench J, Probst A, Winkler DT, Reichwald 
J, Staufenbiel M, Ghetti B, Goedert M and Tolnay M (2013) 'Brain homogenates from human 
tauopathies induce tau inclusions in mouse brain', Proc Natl Acad Sci U S A, 110(23), pp. 9535-40. 
Collinge J and Clarke AR (2007) 'A general model of prion strains and their pathogenicity', Science, 
318(5852), pp. 930-6. 
Collins SJ, Lawson VA and Masters CL (2004) 'Transmissible spongiform encephalopathies', Lancet, 
363(9402), pp. 51-61. 
Colonna M, Turnbull I and Klesney-Tait J (2007) 'The enigmatic function of TREM-2 in 
osteoclastogenesis', Adv Exp Med Biol, 602, pp. 97-105. 
Colonna M and Wang Y (2016) 'TREM2 variants: new keys to decipher Alzheimer disease 
pathogenesis', Nat Rev Neurosci, 17(4), pp. 201-7. 
Condello C, Lemmin T, Stohr J, Nick M, Wu Y, Maxwell AM, Watts JC, Caro CD, Oehler A, Keene 
CD, Bird TD, van Duinen SG, Lannfelt L, Ingelsson M, Graff C, Giles K, DeGrado WF and Prusiner 
SB (2018) 'Structural heterogeneity and intersubject variability of Abeta in familial and sporadic 
Alzheimer's disease', Proc Natl Acad Sci U S A, 115(4), pp. E782-E791. 
Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines 
JL and Pericak-Vance MA (1993) 'Gene dose of apolipoprotein E type 4 allele and the risk of 
Alzheimer's disease in late onset families', Science, 261(5123), pp. 921-3. 
Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM, Benitez BA, Jeng AT, Skorupa T, Carrell 
D, Bertelsen S, Bailey M, McKean D, Shulman JM, De Jager PL, Chibnik L, Bennett DA, Arnold SE, 
Harold D, Sims R, Gerrish A, Williams J, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, 
Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD, Peskind ER, Galasko D, Fagan 
AM, Holtzman DM, Morris JC, Consortium G, Alzheimer's Disease Neuroimaging I, Alzheimer 
Disease Genetic C and Goate AM (2013) 'GWAS of cerebrospinal fluid tau levels identifies risk variants 
for Alzheimer's disease', Neuron, 78(2), pp. 256-68. 
Czako M and Marton L (1994) 'The herpes simplex virus thymidine kinase gene as a conditional 
negative-selection marker gene in Arabidopsis thaliana', Plant Physiol, 104(3), pp. 1067-71. 
Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML and Gan WB 
(2005) 'ATP mediates rapid microglial response to local brain injury in vivo', Nat Neurosci, 8(6), pp. 
752-8. 
De Strooper B, Simons M, Multhaup G, Van Leuven F, Beyreuther K and Dotti CG (1995) 'Production 
of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid 
precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the 
rodent sequence', EMBO J, 14(20), pp. 4932-8. 
DeArmond SJ and Prusiner SB (1995) 'Etiology and pathogenesis of prion diseases', Am J Pathol, 
146(4), pp. 785-811. 
Del-Aguila JL, Fernandez MV, Schindler S, Ibanez L, Deming Y, Ma S, Saef B, Black K, Budde J, 
Norton J, Chasse R, Alzheimer's Disease Neuroimaging I, Harari O, Goate A, Xiong C, Morris JC and 
Cruchaga C (2018) 'Assessment of the Genetic Architecture of Alzheimer's Disease Risk in Rate of 
Memory Decline', J Alzheimers Dis, 62(2), pp. 745-756. 
 
41 
Delabar J, Goldgaber D, Lamour Y, Nicole A, Huret J, de Grouchy J, Brown P, Gajdusek D and Sinet 
P (1987) 'Beta amyloid gene duplication in Alzheimer's disease and karyotypically normal Down 
syndrome', Science, 235(4794), pp. 1390-1392. 
Duran-Aniotz C, Morales R, Moreno-Gonzalez I, Hu PP, Fedynyshyn J and Soto C (2014) 'Aggregate-
depleted brain fails to induce Abeta deposition in a mouse model of Alzheimer's disease', PLoS One, 
9(2), pp. e89014. 
Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, Yan ZX, Roth K, Aguzzi A, 
Staufenbiel M, Walker LC and Jucker M (2009) 'Induction of cerebral beta-amyloidosis: intracerebral 
versus systemic Abeta inoculation', Proc Natl Acad Sci U S A, 106(31), pp. 12926-31. 
Falcon B, Cavallini A, Angers R, Glover S, Murray TK, Barnham L, Jackson S, O'Neill MJ, Isaacs AM, 
Hutton ML, Szekeres PG, Goedert M and Bose S (2015) 'Conformation determines the seeding 
potencies of native and recombinant Tau aggregates', J Biol Chem, 290(2), pp. 1049-65. 
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, 
Risch N and van Duijn CM (1997) 'Effects of age, sex, and ethnicity on the association between 
apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease 
Meta Analysis Consortium', JAMA, 278(16), pp. 1349-56. 
Feuerbach D, Schindler P, Barske C, Joller S, Beng-Louka E, Worringer KA, Kommineni S, Kaykas 
A, Ho DJ, Ye C, Welzenbach K, Elain G, Klein L, Brzak I, Mir AK, Farady CJ, Aichholz R, Popp S, 
George N and Neumann U (2017) 'ADAM17 is the main sheddase for the generation of human 
triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after 
Histidine 157', Neurosci Lett, 660, pp. 109-114. 
Filippini N, MacIntosh BJ, Hough MG, Goodwin GM, Frisoni GB, Smith SM, Matthews PM, 
Beckmann CF and Mackay CE (2009) 'Distinct patterns of brain activity in young carriers of the APOE-
epsilon4 allele', Proc Natl Acad Sci U S A, 106(17), pp. 7209-14. 
Fitz NF, Cronican AA, Saleem M, Fauq AH, Chapman R, Lefterov I and Koldamova R (2012) 'Abca1 
deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted 
replacement mice', J Neurosci, 32(38), pp. 13125-36. 
Forabosco P, Ramasamy A, Trabzuni D, Walker R, Smith C, Bras J, Levine AP, Hardy J, Pocock JM, 
Guerreiro R, Weale ME and Ryten M (2013) 'Insights into TREM2 biology by network analysis of 
human brain gene expression data', Neurobiol Aging, 34(12), pp. 2699-714. 
Fox NC, Crum WR, Scahill RI, Stevens JM, Janssen JC and Rossor MN (2001) 'Imaging of onset and 
progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance 
images', Lancet, 358(9277), pp. 201-5. 
Fritschi SK, Cintron A, Ye L, Mahler J, Buhler A, Baumann F, Neumann M, Nilsson KP, Hammarstrom 
P, Walker LC and Jucker M (2014a) 'Abeta seeds resist inactivation by formaldehyde', Acta 
Neuropathol, 128(4), pp. 477-84. 
Fritschi SK, Langer F, Kaeser SA, Maia LF, Portelius E, Pinotsi D, Kaminski CF, Winkler DT, Maetzler 
W, Keyvani K, Spitzer P, Wiltfang J, Kaminski Schierle GS, Zetterberg H, Staufenbiel M and Jucker 
M (2014b) 'Highly potent soluble amyloid-beta seeds in human Alzheimer brain but not cerebrospinal 
fluid', Brain, 137(Pt 11), pp. 2909-2915. 
Funato H, Yoshimura M, Yamazaki T, Saido TC, Ito Y, Yokofujita J, Okeda R and Ihara Y (1998) 
'Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-
positive diffuse plaques in the aged human brain', Am J Pathol, 152(4), pp. 983-92. 
 
42 
Gajdusek DC (1977) 'Unconventional viruses and the origin and disappearance of kuru', Science, 
197(4307), pp. 943-60. 
Gajdusek DC (1994) 'Spontaneous generation of infectious nucleating amyloids in the transmissible 
and nontransmissible cerebral amyloidoses', Mol Neurobiol, 8(1), pp. 1-13. 
Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, 
Donaldson T, Gillespie F and et al. (1995) 'Alzheimer-type neuropathology in transgenic mice 
overexpressing V717F beta-amyloid precursor protein', Nature, 373(6514), pp. 523-7. 
Ghezzi L, Carandini T, Arighi A, Fenoglio C, Arcaro M, De Riz M, Pietroboni AM, Fumagalli GG, 
Basilico P, Calvi A, Scarioni M, Colombi A, Serpente M, Marotta G, Benti R, Scarpini E and Galimberti 
D (2017) 'Evidence of CNS beta-amyloid deposition in Nasu-Hakola disease due to the TREM2 Q33X 
mutation', Neurology, 89(24), pp. 2503-2505. 
Giraldo M, Lopera F, Siniard AL, Corneveaux JJ, Schrauwen I, Carvajal J, Munoz C, Ramirez-Restrepo 
M, Gaiteri C, Myers AJ, Caselli RJ, Kosik KS, Reiman EM and Huentelman MJ (2013) 'Variants in 
triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant 
frontotemporal lobar degeneration and Alzheimer's disease', Neurobiol Aging, 34(8), pp. 2077 e11-8. 
Gispert JD, Suarez-Calvet M, Monte GC, Tucholka A, Falcon C, Rojas S, Rami L, Sanchez-Valle R, 
Llado A, Kleinberger G, Haass C and Molinuevo JL (2016) 'Cerebrospinal fluid sTREM2 levels are 
associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease', 
Alzheimers Dement, 12(12), pp. 1259-1272. 
Glebov K, Wunderlich P, Karaca I and Walter J (2016) 'Functional involvement of gamma-secretase in 
signaling of the triggering receptor expressed on myeloid cells-2 (TREM2)', J Neuroinflammation, 13, 
pp. 17. 
Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving 
N, James L and et al. (1991) 'Segregation of a missense mutation in the amyloid precursor protein gene 
with familial Alzheimer's disease', Nature, 349(6311), pp. 704-6. 
Goedert M (2015) 'NEURODEGENERATION. Alzheimer's and Parkinson's diseases: The prion 
concept in relation to assembled Abeta, tau, and alpha-synuclein', Science, 349(6248), pp. 1255555. 
Goedert M, Masuda-Suzukake M and Falcon B (2017) 'Like prions: the propagation of aggregated tau 
and alpha-synuclein in neurodegeneration', Brain, 140(2), pp. 266-278. 
Gonneaud J, Arenaza-Urquijo EM, Mezenge F, Landeau B, Gaubert M, Bejanin A, de Flores R, Wirth 
M, Tomadesso C, Poisnel G, Abbas A, Desgranges B and Chetelat G (2017) 'Increased florbetapir 
binding in the temporal neocortex from age 20 to 60 years', Neurology, 89(24), pp. 2438-2446. 
Gotz J, Chen F, van Dorpe J and Nitsch RM (2001) 'Formation of neurofibrillary tangles in P301l tau 
transgenic mice induced by Abeta 42 fibrils', Science, 293(5534), pp. 1491-5. 
Götz J, Streffer JR, David D, Schild A, Hoerndli F, Pennanen L, Kurosinski P and Chen F (2004) 
'Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and 
therapy', Molecular Psychiatry, 9(7), pp. 664-683. 
Goudsmit J, Morrow CH, Asher DM, Yanagihara RT, Masters CL, Gibbs CJ, Jr. and Gajdusek DC 




Grathwohl SA, Kalin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, Odenthal J, Radde R, Eldh 
T, Gandy S, Aguzzi A, Staufenbiel M, Mathews PM, Wolburg H, Heppner FL and Jucker M (2009) 
'Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia', 
Nat Neurosci, 12(11), pp. 1361-3. 
Guerreiro R and Bras J (2015) 'The age factor in Alzheimer's disease', Genome Med, 7, pp. 106. 
Guerreiro R and Hardy J (2013) 'TREM2 and neurodegenerative disease', N Engl J Med, 369(16), pp. 
1569-70. 
Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, Cruchaga C, Sassi C, Kauwe 
JS, Younkin S, Hazrati L, Collinge J, Pocock J, Lashley T, Williams J, Lambert JC, Amouyel P, Goate 
A, Rademakers R, Morgan K, Powell J, St George-Hyslop P, Singleton A, Hardy J and Alzheimer 
Genetic Analysis G (2013a) 'TREM2 variants in Alzheimer's disease', N Engl J Med, 368(2), pp. 117-
27. 
Guerreiro RJ, Baquero M, Blesa R, Boada M, Bras JM, Bullido MJ, Calado A, Crook R, Ferreira C, 
Frank A, Gomez-Isla T, Hernandez I, Lleo A, Machado A, Martinez-Lage P, Masdeu J, Molina-Porcel 
L, Molinuevo JL, Pastor P, Perez-Tur J, Relvas R, Oliveira CR, Ribeiro MH, Rogaeva E, Sa A, 
Samaranch L, Sanchez-Valle R, Santana I, Tarraga L, Valdivieso F, Singleton A, Hardy J and Clarimon 
J (2010) 'Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel 
mutations in presenilins and APP', Neurobiol Aging, 31(5), pp. 725-31. 
Guerreiro RJ, Lohmann E, Bras JM, Gibbs JR, Rohrer JD, Gurunlian N, Dursun B, Bilgic B, Hanagasi 
H, Gurvit H, Emre M, Singleton A and Hardy J (2013b) 'Using exome sequencing to reveal mutations 
in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement', JAMA 
Neurol, 70(1), pp. 78-84. 
Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski 
JQ and Lee VM (2013) 'Distinct alpha-synuclein strains differentially promote tau inclusions in 
neurons', Cell, 154(1), pp. 103-17. 
Guo JL and Lee VM (2014) 'Cell-to-cell transmission of pathogenic proteins in neurodegenerative 
diseases', Nat Med, 20(2), pp. 130-8. 
Guo JL, Narasimhan S, Changolkar L, He Z, Stieber A, Zhang B, Gathagan RJ, Iba M, McBride JD, 
Trojanowski JQ and Lee VM (2016) 'Unique pathological tau conformers from Alzheimer's brains 
transmit tau pathology in nontransgenic mice', J Exp Med, 213(12), pp. 2635-2654. 
Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM and Mattson MP (1999) 'Increased 
vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice', Nat 
Med, 5(1), pp. 101-6. 
Haass C and Selkoe DJ (2007) 'Soluble protein oligomers in neurodegeneration: lessons from the 
Alzheimer's amyloid beta-peptide', Nat Rev Mol Cell Biol, 8(2), pp. 101-12. 
Haass C and Willem M (2019) 'Secreted APP Modulates Synaptic Activity: A Novel Target for 
Therapeutic Intervention?', Neuron, 101(4), pp. 557-559. 
Hammond TR, Dufort C, Dissing-Olesen L, Giera S, Young A, Wysoker A, Walker AJ, Gergits F, 
Segel M, Nemesh J, Marsh SE, Saunders A, Macosko E, Ginhoux F, Chen J, Franklin RJM, Piao X, 
McCarroll SA and Stevens B (2018) 'Single-Cell RNA Sequencing of Microglia throughout the Mouse 
Lifespan and in the Injured Brain Reveals Complex Cell-State Changes', Immunity. 
 
44 
Hardy J and Allsop D (1991) 'Amyloid deposition as the central event in the aetiology of Alzheimer's 
disease', Trends Pharmacol Sci, 12(10), pp. 383-8. 
Hardy J and Higgins G (1992) 'Alzheimer's disease: the amyloid cascade hypothesis', Science, 
256(5054), pp. 184-185. 
Hardy J and Selkoe DJ (2002) 'The amyloid hypothesis of Alzheimer's disease: progress and problems 
on the road to therapeutics', Science, 297(5580), pp. 353-6. 
Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, 
Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, 
Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore 
PA, Craig D, McGuinness B, Todd S, Holmes C, et al. (2009) 'Genome-wide association study identifies 
variants at CLU and PICALM associated with Alzheimer's disease', Nat Genet, 41(10), pp. 1088-93. 
Harper JD, Lieber CM and Lansbury PT, Jr. (1997) 'Atomic force microscopic imaging of seeded fibril 
formation and fibril branching by the Alzheimer's disease amyloid-beta protein', Chem Biol, 4(12), pp. 
951-9. 
Hasegawa K, Yamaguchi I, Omata S, Gejyo F and Naiki H (1999) 'Interaction between A beta(1-42) 
and A beta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro', Biochemistry, 38(47), pp. 
15514-21. 
He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L, Zhang B, Gathagan RJ, Yue C, 
Dengler C, Stieber A, Nitla M, Coulter DA, Abel T, Brunden KR, Trojanowski JQ and Lee VM (2018) 
'Amyloid-beta plaques enhance Alzheimer's brain tau-seeded pathologies by facilitating neuritic plaque 
tau aggregation', Nat Med, 24(1), pp. 29-38. 
Heilbronner G, Eisele YS, Langer F, Kaeser SA, Novotny R, Nagarathinam A, Aslund A, 
Hammarstrom P, Nilsson KP and Jucker M (2013) 'Seeded strain-like transmission of beta-amyloid 
morphotypes in APP transgenic mice', EMBO Rep, 14(11), pp. 1017-22. 
Henjum K, Almdahl IS, Arskog V, Minthon L, Hansson O, Fladby T and Nilsson LN (2016) 
'Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease', Alzheimers Res Ther, 8(1), pp. 
17. 
Heslegrave A, Heywood W, Paterson R, Magdalinou N, Svensson J, Johansson P, Ohrfelt A, Blennow 
K, Hardy J, Schott J, Mills K and Zetterberg H (2016) 'Increased cerebrospinal fluid soluble TREM2 
concentration in Alzheimer's disease', Mol Neurodegener, 11, pp. 3. 
Hickman SE, Allison EK and El Khoury J (2008) 'Microglial dysfunction and defective beta-amyloid 
clearance pathways in aging Alzheimer's disease mice', J Neurosci, 28(33), pp. 8354-60. 
Higuchi M, Ji B, Maeda J, Sahara N and Suhara T (2016) 'In vivoimaging of neuroinflammation in 
Alzheimer's disease', Clinical and Experimental Neuroimmunology, 7(2), pp. 139-144. 
Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I, Mueller R, 
Morgan D, Sanders S, Zehr C, O'Campo K, Hardy J, Prada CM, Eckman C, Younkin S, Hsiao K and 
Duff K (1998) 'Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid 
precursor protein and presenilin 1 transgenes', Nat Med, 4(1), pp. 97-100. 
Hollingworth P and Harold D and Sims R and Gerrish A and Lambert JC and Carrasquillo MM and 
Abraham R and Hamshere ML and Pahwa JS and Moskvina V and Dowzell K and Jones N and Stretton 
A and Thomas C and Richards A and Ivanov D and Widdowson C and Chapman J and Lovestone S 
and Powell J and Proitsi P and Lupton MK and Brayne C and Rubinsztein DC and Gill M and Lawlor 
 
45 
B and Lynch A and Brown KS and Passmore PA and Craig D, et al. (2011) 'Common variants at 
ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease', Nat 
Genet, 43(5), pp. 429-35. 
Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, 
McKeel D, Wozniak D and Paul SM (2000) 'Apolipoprotein E isoform-dependent amyloid deposition 
and neuritic degeneration in a mouse model of Alzheimer's disease', Proc Natl Acad Sci U S A, 97(6), 
pp. 2892-7. 
Holtzman DM and Fagan AM (1998) 'Potential role of apoE in structural plasticity in the nervous 
system; implications for disorders of the central nervous system', Trends Cardiovasc Med, 8(6), pp. 
250-5. 
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F and Cole G (1996) 
'Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice', Science, 
274(5284), pp. 99-102. 
Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H, Pickering-Brown S, Chakraverty S, 
Isaacs A, Grover A, Hackett J, Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens M, 
de Graaff E, Wauters E, van Baren J, Hillebrand M, Joosse M, Kwon JM, Nowotny P, Che LK, Norton 
J, Morris JC, Reed LA, Trojanowski J, Basun H, et al. (1998) 'Association of missense and 5'-splice-
site mutations in tau with the inherited dementia FTDP-17', Nature, 393(6686), pp. 702-5. 
Huynh TV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H, Roh J, Finn MB, Sullivan PM, 
Esparza TJ, Stewart FR, Mahan TE, Ulrich JD, Cole T and Holtzman DM (2017) 'Age-Dependent 
Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of beta-amyloidosis', Neuron, 
96(5), pp. 1013-1023 e4. 
Insel PS, Ossenkoppele R, Gessert D, Jagust W, Landau S, Hansson O, Weiner MW and Mattsson N 
(2017) 'Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and 
Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease', Frontiers in 
Neuroscience, 11. 
Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, Copeland NG, Lee MK, 
Younkin LH, Wagner SL, Younkin SG and Borchelt DR (2004) 'Mutant presenilins specifically elevate 
the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific 
gamma secretase', Hum Mol Genet, 13(2), pp. 159-70. 
Jarrett JT and Lansbury PT, Jr. (1993) 'Seeding "one-dimensional crystallization" of amyloid: a 
pathogenic mechanism in Alzheimer's disease and scrapie?', Cell, 73(6), pp. 1055-8. 
Jay TR, Hirsch AM, Broihier ML, Miller CM, Neilson LE, Ransohoff RM, Lamb BT and Landreth GE 
(2017) 'Disease Progression-Dependent Effects of TREM2 Deficiency in a Mouse Model of 
Alzheimer's Disease', J Neurosci, 37(3), pp. 637-647. 
Jay TR, Miller CM, Cheng PJ, Graham LC, Bemiller S, Broihier ML, Xu G, Margevicius D, Karlo JC, 
Sousa GL, Cotleur AC, Butovsky O, Bekris L, Staugaitis SM, Leverenz JB, Pimplikar SW, Landreth 
GE, Howell GR, Ransohoff RM and Lamb BT (2015) 'TREM2 deficiency eliminates TREM2+ 
inflammatory macrophages and ameliorates pathology in Alzheimer's disease mouse models', J Exp 
Med, 212(3), pp. 287-95. 
Jendresen C, Arskog V, Daws MR and Nilsson LN (2017) 'The Alzheimer's disease risk factors 




Jessen NA, Munk AS, Lundgaard I and Nedergaard M (2015) 'The Glymphatic System: A Beginner's 
Guide', Neurochem Res, 40(12), pp. 2583-99. 
Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, 
Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P and Landreth 
GE (2008) 'ApoE promotes the proteolytic degradation of Abeta', Neuron, 58(5), pp. 681-93. 
Jiang T, Hou JK, Gao Q, Yu JT, Zhou JS, Zhao HD and Zhang YD (2016) 'TREM2 p.H157Y Variant 
and the Risk of Alzheimer's Disease: A Meta-Analysis Involving 14,510 Subjects', Curr Neurovasc 
Res, 13(4), pp. 318-320. 
Jiang T, Yu JT, Zhu XC, Tan MS, Gu LZ, Zhang YD and Tan L (2014) 'Triggering receptor expressed 
on myeloid cells 2 knockdown exacerbates aging-related neuroinflammation and cognitive deficiency 
in senescence-accelerated mouse prone 8 mice', Neurobiol Aging, 35(6), pp. 1243-51. 
Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D, Norton JB, Hsu S, Harari O, Cai Y, 
Bertelsen S, Goate AM and Cruchaga C (2014) 'Coding variants in TREM2 increase risk for 
Alzheimer's disease', Hum Mol Genet, 23(21), pp. 5838-46. 
Jin SC, Carrasquillo MM, Benitez BA, Skorupa T, Carrell D, Patel D, Lincoln S, Krishnan S, 
Kachadoorian M, Reitz C, Mayeux R, Wingo TS, Lah JJ, Levey AI, Murrell J, Hendrie H, Foroud T, 
Graff-Radford NR, Goate AM, Cruchaga C and Ertekin-Taner N (2015) 'TREM2 is associated with 
increased risk for Alzheimer's disease in African Americans', Mol Neurodegener, 10, pp. 19. 
Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson H, Sulem P, 
Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Liu Y, Lu Y, Bhangale T, Graham RR, 
Huttenlocher J, Bjornsdottir G, Andreassen OA, Jonsson EG, Palotie A, Behrens TW, Magnusson OT, 
Kong A, Thorsteinsdottir U, Watts RJ and Stefansson K (2012) 'A mutation in APP protects against 
Alzheimer's disease and age-related cognitive decline', Nature, 488(7409), pp. 96-9. 
Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, Bjornsson S, Huttenlocher 
J, Levey AI, Lah JJ, Rujescu D, Hampel H, Giegling I, Andreassen OA, Engedal K, Ulstein I, Djurovic 
S, Ibrahim-Verbaas C, Hofman A, Ikram MA, van Duijn CM, Thorsteinsdottir U, Kong A and 
Stefansson K (2013) 'Variant of TREM2 associated with the risk of Alzheimer's disease', N Engl J Med, 
368(2), pp. 107-16. 
Jonsson T and Stefansson K (2013) 'TREM2 and neurodegenerative disease', N Engl J Med, 369(16), 
pp. 1568-9. 
Jucker M and Walker LC (2013) 'Self-propagation of pathogenic protein aggregates in 
neurodegenerative diseases', Nature, 501(7465), pp. 45-51. 
Kaifu T, Nakahara J, Inui M, Mishima K, Momiyama T, Kaji M, Sugahara A, Koito H, Ujike-Asai A, 
Nakamura A, Kanazawa K, Tan-Takeuchi K, Iwasaki K, Yokoyama WM, Kudo A, Fujiwara M, Asou 
H and Takai T (2003) 'Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in 
DAP12-deficient mice', Journal of Clinical Investigation, 111(3), pp. 323-332. 
Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE and Walker LC 
(2000) 'Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in 
beta -amyloid precursor protein-transgenic mice', J Neurosci, 20(10), pp. 3606-11. 
Kang SS, Ebbert MTW, Baker KE, Cook C, Wang X, Sens JP, Kocher JP, Petrucelli L and Fryer JD 
(2018) 'Microglial translational profiling reveals a convergent APOE pathway from aging, amyloid, 
and tau', J Exp Med, 215(9), pp. 2235-2245. 
 
47 
Karch CM, Cruchaga C and Goate AM (2014) 'Alzheimer's disease genetics: from the bench to the 
clinic', Neuron, 83(1), pp. 11-26. 
Katsouri L and Georgopoulos S (2011) 'Lack of LDL receptor enhances amyloid deposition and 
decreases glial response in an Alzheimer's disease mouse model', PLoS One, 6(7), pp. e21880. 
Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, David E, 
Baruch K, Lara-Astaiso D, Toth B, Itzkovitz S, Colonna M, Schwartz M and Amit I (2017) 'A Unique 
Microglia Type Associated with Restricting Development of Alzheimer's Disease', Cell, 169(7), pp. 
1276-1290 e17. 
Kim J, Basak JM and Holtzman DM (2009a) 'The role of apolipoprotein E in Alzheimer's disease', 
Neuron, 63(3), pp. 287-303. 
Kim J, Castellano JM, Jiang H, Basak JM, Parsadanian M, Pham V, Mason SM, Paul SM and Holtzman 
DM (2009b) 'Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid 
deposition and increases extracellular A beta clearance', Neuron, 64(5), pp. 632-44. 
Kim J, Eltorai AE, Jiang H, Liao F, Verghese PB, Kim J, Stewart FR, Basak JM and Holtzman DM 
(2012) 'Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Abeta 
amyloidosis', J Exp Med, 209(12), pp. 2149-56. 
Kim J, Yoon H, Horie T, Burchett JM, Restivo JL, Rotllan N, Ramirez CM, Verghese PB, Ihara M, 
Hoe HS, Esau C, Fernandez-Hernando C, Holtzman DM, Cirrito JR, Ono K and Kim J (2015) 
'microRNA-33 Regulates ApoE Lipidation and Amyloid-beta Metabolism in the Brain', J Neurosci, 
35(44), pp. 14717-26. 
Kleinberger G, Brendel M, Mracsko E, Wefers B, Groeneweg L, Xiang X, Focke C, Deussing M, 
Suarez-Calvet M, Mazaheri F, Parhizkar S, Pettkus N, Wurst W, Feederle R, Bartenstein P, Mueggler 
T, Arzberger T, Knuesel I, Rominger A and Haass C (2017) 'The FTD-like syndrome causing TREM2 
T66M mutation impairs microglia function, brain perfusion, and glucose metabolism', EMBO J, 36(13), 
pp. 1837-1853. 
Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E, Struyfs H, Pettkus N, 
Wenninger-Weinzierl A, Mazaheri F, Tahirovic S, Lleo A, Alcolea D, Fortea J, Willem M, Lammich 
S, Molinuevo JL, Sanchez-Valle R, Antonell A, Ramirez A, Heneka MT, Sleegers K, van der Zee J, 
Martin JJ, Engelborghs S, Demirtas-Tatlidede A, Zetterberg H, Van Broeckhoven C, Gurvit H, Wyss-
Coray T, Hardy J, Colonna M and Haass C (2014) 'TREM2 mutations implicated in neurodegeneration 
impair cell surface transport and phagocytosis', Sci Transl Med, 6(243), pp. 243ra86. 
Klunemann HH, Ridha BH, Magy L, Wherrett JR, Hemelsoet DM, Keen RW, De Bleecker JL, Rossor 
MN, Marienhagen J, Klein HE, Peltonen L and Paloneva J (2005) 'The genetic causes of basal ganglia 
calcification, dementia, and bone cysts: DAP12 and TREM2', Neurology, 64(9), pp. 1502-7. 
Knowles TP, Waudby CA, Devlin GL, Cohen SI, Aguzzi A, Vendruscolo M, Terentjev EM, Welland 
ME and Dobson CM (2009) 'An analytical solution to the kinetics of breakable filament assembly', 
Science, 326(5959), pp. 1533-7. 
Kober DL, Alexander-Brett JM, Karch CM, Cruchaga C, Colonna M, Holtzman MJ and Brett TJ (2016) 
'Neurodegenerative disease mutations in TREM2 reveal a functional surface and distinct loss-of-
function mechanisms', Elife, 5. 
Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR 
and Paul SM (2004) 'Apolipoprotein E promotes astrocyte colocalization and degradation of deposited 
amyloid-beta peptides', Nat Med, 10(7), pp. 719-26. 
 
48 
Koldamova R, Staufenbiel M and Lefterov I (2005) 'Lack of ABCA1 considerably decreases brain 
ApoE level and increases amyloid deposition in APP23 mice', J Biol Chem, 280(52), pp. 43224-35. 
Konishi H and Kiyama H (2018) 'Microglial TREM2/DAP12 Signaling: A Double-Edged Sword in 
Neural Diseases', Front Cell Neurosci, 12, pp. 206. 
Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu 
Y, Fanek Z, Greco DJ, Smith ST, Tweet G, Humulock Z, Zrzavy T, Conde-Sanroman P, Gacias M, 
Weng Z, Chen H, Tjon E, Mazaheri F, Hartmann K, Madi A, Ulrich JD, Glatzel M, Worthmann A, 
Heeren J, Budnik B, Lemere C, Ikezu T, Heppner FL, Litvak V, Holtzman DM, Lassmann H, Weiner 
HL, Ochando J, Haass C and Butovsky O (2017) 'The TREM2-APOE Pathway Drives the 
Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases', Immunity, 
47(3), pp. 566-581 e9. 
Kretner B, Trambauer J, Fukumori A, Mielke J, Kuhn PH, Kremmer E, Giese A, Lichtenthaler SF, 
Haass C, Arzberger T and Steiner H (2016) 'Generation and deposition of Aβ43 by the virtually inactive 
presenilin 1 L435F mutant contradicts the presenilin loss of function hypothesis of Alzheimer's 
disease', EMBO Molecular Medicine, 8(5), pp. 458-465. 
LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS and Frail DE (1994) 'Isoform-specific 
binding of apolipoprotein E to beta-amyloid', J Biol Chem, 269(38), pp. 23403-6. 
LaFerla FM and Green KN (2012) 'Animal Models of Alzheimer Disease', Cold Spring Harbor 
Perspectives in Medicine, 2(11), pp. a006320-a006320. 
Lambert JC and Ibrahim-Verbaas CA and Harold D and Naj AC and Sims R and Bellenguez C and 
DeStafano AL and Bis JC and Beecham GW and Grenier-Boley B and Russo G and Thorton-Wells TA 
and Jones N and Smith AV and Chouraki V and Thomas C and Ikram MA and Zelenika D and 
Vardarajan BN and Kamatani Y and Lin CF and Gerrish A and Schmidt H and Kunkle B and Dunstan 
ML and Ruiz A and Bihoreau MT and Choi SH and Reitz C and Pasquier F, et al. (2013) 'Meta-analysis 
of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease', Nat Genet, 45(12), 
pp. 1452-8. 
Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC and Jucker M (2011) 'Soluble Abeta seeds 
are potent inducers of cerebral beta-amyloid deposition', J Neurosci, 31(41), pp. 14488-95. 
Lanier LL (2009) 'DAP10- and DAP12-associated receptors in innate immunity', Immunol Rev, 227(1), 
pp. 150-60. 
Lansbury PT, Jr. (1997) 'Structural neurology: are seeds at the root of neuronal degeneration?', Neuron, 
19(6), pp. 1151-4. 
Le Ber I, De Septenville A, Guerreiro R, Bras J, Camuzat A, Caroppo P, Lattante S, Couarch P, Kabashi 
E, Bouya-Ahmed K, Dubois B and Brice A (2014) 'Homozygous TREM2 mutation in a family with 
atypical frontotemporal dementia', Neurobiol Aging, 35(10), pp. 2419 e23-2419 e25. 
Lee CY and Landreth GE (2010) 'The role of microglia in amyloid clearance from the AD brain', J 
Neural Transm (Vienna), 117(8), pp. 949-60. 
Lee SJ, Desplats P, Sigurdson C, Tsigelny I and Masliah E (2010) 'Cell-to-cell transmission of non-
prion protein aggregates', Nat Rev Neurol, 6(12), pp. 702-6. 
Li N, Liu K, Qiu Y, Ren Z, Dai R, Deng Y and Qing H (2016) 'Effect of Presenilin Mutations on APP 
Cleavage; Insights into the Pathogenesis of FAD', Front Aging Neurosci, 8, pp. 51. 
 
49 
Liao F, Hori Y, Hudry E, Bauer AQ, Jiang H, Mahan TE, Lefton KB, Zhang TJ, Dearborn JT, Kim J, 
Culver JP, Betensky R, Wozniak DF, Hyman BT and Holtzman DM (2014) 'Anti-ApoE antibody given 
after plaque onset decreases Abeta accumulation and improves brain function in a mouse model of 
Abeta amyloidosis', J Neurosci, 34(21), pp. 7281-92. 
Lichtenthaler SF, Wang R, Grimm H, Uljon SN, Masters CL and Beyreuther K (1999) 'Mechanism of 
the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning 
mutagenesis of the transmembrane domain of the amyloid precursor protein', Proc Natl Acad Sci U S 
A, 96(6), pp. 3053-8. 
Lill CM, Rengmark A, Pihlstrom L, Fogh I, Shatunov A, Sleiman PM, Wang LS, Liu T, Lassen CF, 
Meissner E, Alexopoulos P, Calvo A, Chio A, Dizdar N, Faltraco F, Forsgren L, Kirchheiner J, Kurz 
A, Larsen JP, Liebsch M, Linder J, Morrison KE, Nissbrandt H, Otto M, Pahnke J, Partch A, Restagno 
G, Rujescu D, Schnack C, Shaw CE, et al. (2015) 'The role of TREM2 R47H as a risk factor for 
Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's 
disease', Alzheimers Dement, 11(12), pp. 1407-1416. 
Liu CC, Zhao N, Fu Y, Wang N, Linares C, Tsai CW and Bu G (2017) 'ApoE4 Accelerates Early 
Seeding of Amyloid Pathology', Neuron, 96(5), pp. 1024-1032 e3. 
Lucin KM and Wyss-Coray T (2009) 'Immune activation in brain aging and neurodegeneration: too 
much or too little?', Neuron, 64(1), pp. 110-22. 
Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ and Lee VM (2012) 'Pathological 
alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice', 
Science, 338(6109), pp. 949-53. 
Ma L, Allen M, Sakae N, Ertekin-Taner N, Graff-Radford NR, Dickson DW, Younkin SG and Sevlever 
D (2016) 'Expression and processing analyses of wild type and p.R47H TREM2 variant in Alzheimer's 
disease brains', Mol Neurodegener, 11(1), pp. 72. 
Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM and 
Zlokovic BV (2018) 'Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-
beta42 by LRP1-dependent apolipoprotein E isoform-specific mechanism', Mol Neurodegener, 13(1), 
pp. 57. 
Mahley RW and Huang Y (2012) 'Apolipoprotein e sets the stage: response to injury triggers 
neuropathology', Neuron, 76(5), pp. 871-85. 
Maia LF, Kaeser SA, Reichwald J, Hruscha M, Martus P, Staufenbiel M and Jucker M (2013) 'Changes 
in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor 
protein', Sci Transl Med, 5(194), pp. 194re2. 
Masuda T, Sankowski R, Staszewski O, Bottcher C, Amann L, Scheiwe C, Sagar, Nessler S, Kunz P, 
van Loo G, Coenen VA, Reinacher PC, Michel A, Sure U, Gold R, Grun D, Priller J, Stadelmann C and 
Prinz M (2019) 'Spatial and temporal heterogeneity of mouse and human microglia at single-cell 
resolution', Nature, 566(7744), pp. 388-392. 
Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE and Bateman 
RJ (2010) 'Decreased clearance of CNS beta-amyloid in Alzheimer's disease', Science, 330(6012), pp. 
1774. 
Mazaheri F, Snaidero N, Kleinberger G, Madore C, Daria A, Werner G, Krasemann S, Capell A, 
Trumbach D, Wurst W, Brunner B, Bultmann S, Tahirovic S, Kerschensteiner M, Misgeld T, Butovsky 
 
50 
O and Haass C (2017) 'TREM2 deficiency impairs chemotaxis and microglial responses to neuronal 
injury', EMBO Rep, 18(7), pp. 1186-1198. 
Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander 
A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM, Ghiso J, 
Staufenbiel M, Walker LC and Jucker M (2006) 'Exogenous induction of cerebral beta-amyloidogenesis 
is governed by agent and host', Science, 313(5794), pp. 1781-4. 
Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, Rozkalne A, 
Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ and Hyman BT (2008) 'Rapid appearance and 
local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease', Nature, 451(7179), 
pp. 720-4. 
Michaelson DM (2014) 'APOE epsilon4: the most prevalent yet understudied risk factor for Alzheimer's 
disease', Alzheimers Dement, 10(6), pp. 861-8. 
Miller MB, Wang DW, Wang F, Noble GP, Ma J, Woods VL, Jr., Li S and Supattapone S (2013) 
'Cofactor molecules induce structural transformation during infectious prion formation', Structure, 
21(11), pp. 2061-8. 
Mitani Y, Yarimizu J, Saita K, Uchino H, Akashiba H, Shitaka Y, Ni K and Matsuoka N (2012) 
'Differential effects between gamma-secretase inhibitors and modulators on cognitive function in 
amyloid precursor protein-transgenic and nontransgenic mice', J Neurosci, 32(6), pp. 2037-50. 
Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, Capell A, Kaether C, Zheng H, Ghetti B, Haass 
C and Steiner H (2002) 'Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch 
and APP intracellular domains independent of their effect on Abeta 42 production', Proc Natl Acad Sci 
U S A, 99(12), pp. 8025-30. 
Morales R, Duran-Aniotz C, Castilla J, Estrada LD and Soto C (2012) 'De novo induction of amyloid-
beta deposition in vivo', Mol Psychiatry, 17(12), pp. 1347-53. 
Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM and Mintun MA (2010) 'APOE 
predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging', Ann Neurol, 67(1), 
pp. 122-31. 
Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-
Wood K and McConlogue L (2000) 'High-level neuronal expression of abeta 1-42 in wild-type human 
amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation', J Neurosci, 
20(11), pp. 4050-8. 
Muller UC, Deller T and Korte M (2017) 'Not just amyloid: physiological functions of the amyloid 
precursor protein family', Nat Rev Neurosci, 18(5), pp. 281-298. 
Musiek ES and Holtzman DM (2015) 'Three dimensions of the amyloid hypothesis: time, space and 
'wingmen'', Nat Neurosci, 18(6), pp. 800-6. 
Naj AC and Jun G and Beecham GW and Wang LS and Vardarajan BN and Buros J and Gallins PJ and 
Buxbaum JD and Jarvik GP and Crane PK and Larson EB and Bird TD and Boeve BF and Graff-
Radford NR and De Jager PL and Evans D and Schneider JA and Carrasquillo MM and Ertekin-Taner 
N and Younkin SG and Cruchaga C and Kauwe JS and Nowotny P and Kramer P and Hardy J and 
Huentelman MJ and Myers AJ and Barmada MM and Demirci FY and Baldwin CT, et al. (2011) 
'Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset 
Alzheimer's disease', Nat Genet, 43(5), pp. 436-41. 
 
51 
Nataf S, Anginot A, Vuaillat C, Malaval L, Fodil N, Chereul E, Langlois J-B, Dumontel C, Cavillon G, 
Confavreux C, Mazzorana M, Vico L, Belin M-F, Vivier E, Tomasello E and Jurdic P (2005) 'Brain 
and Bone Damage in KARAP/DAP12 Loss-of-Function Mice Correlate with Alterations in Microglia 
and Osteoclast Lineages', The American Journal of Pathology, 166(1), pp. 275-286. 
Neumann H and Takahashi K (2007) 'Essential role of the microglial triggering receptor expressed on 
myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis', J Neuroimmunol, 184(1-2), 
pp. 92-9. 
Neumann M, Tolnay M and Mackenzie IR (2009) 'The molecular basis of frontotemporal dementia', 
Expert Rev Mol Med, 11, pp. e23. 
Novotny R, Langer F, Mahler J, Skodras A, Vlachos A, Wegenast-Braun BM, Kaeser SA, Neher JJ, 
Eisele YS, Pietrowski MJ, Nilsson KP, Deller T, Staufenbiel M, Heimrich B and Jucker M (2016) 
'Conversion of Synthetic Abeta to In Vivo Active Seeds and Amyloid Plaque Formation in a 
Hippocampal Slice Culture Model', J Neurosci, 36(18), pp. 5084-93. 
Paloneva J, Autti T, Raininko R, Partanen J, Salonen O, Puranen M, Hakola P and Haltia M (2001) 
'CNS manifestations of Nasu-Hakola disease: a frontal dementia with bone cysts', Neurology, 56(11), 
pp. 1552-8. 
Paloneva J, Mandelin J, Kiialainen A, Bohling T, Prudlo J, Hakola P, Haltia M, Konttinen YT and 
Peltonen L (2003) 'DAP12/TREM2 deficiency results in impaired osteoclast differentiation and 
osteoporotic features', J Exp Med, 198(4), pp. 669-75. 
Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R, Bianchin M, Bird T, 
Miranda R, Salmaggi A, Tranebjaerg L, Konttinen Y and Peltonen L (2002) 'Mutations in two genes 
encoding different subunits of a receptor signaling complex result in an identical disease phenotype', 
Am J Hum Genet, 71(3), pp. 656-62. 
Paresce DM, Chung H and Maxfield FR (1997) 'Slow degradation of aggregates of the Alzheimer's 
disease amyloid beta-protein by microglial cells', J Biol Chem, 272(46), pp. 29390-7. 
Paresce DM, Ghosh RN and Maxfield FR (1996) 'Microglial cells internalize aggregates of the 
Alzheimer's disease amyloid beta-protein via a scavenger receptor', Neuron, 17(3), pp. 553-65. 
Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, 
Ghasemigharagoz A, Katzmarski N, Krasemann S, Lichtenthaler SF, Muller SA, Colombo A, Monasor 
LS, Tahirovic S, Herms J, Willem M, Pettkus N, Butovsky O, Bartenstein P, Edbauer D, Rominger A, 
Erturk A, Grathwohl SA, Neher JJ, Holtzman DM, Meyer-Luehmann M and Haass C (2019) 'Loss of 
TREM2 function increases amyloid seeding but reduces plaque-associated ApoE', Nat Neurosci. 
Park JS, Ji IJ, An HJ, Kang MJ, Kang SW, Kim DH and Yoon SY (2015) 'Disease-Associated Mutations 
of TREM2 Alter the Processing of N-Linked Oligosaccharides in the Golgi Apparatus', Traffic, 16(5), 
pp. 510-8. 
Piccio L, Buonsanti C, Mariani M, Cella M, Gilfillan S, Cross AH, Colonna M and Panina-Bordignon 
P (2007) 'Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis', Eur J 
Immunol, 37(5), pp. 1290-301. 
Piccio L, Deming Y, Del-Aguila JL, Ghezzi L, Holtzman DM, Fagan AM, Fenoglio C, Galimberti D, 
Borroni B and Cruchaga C (2016) 'Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease 
and associated with mutation status', Acta Neuropathol, 131(6), pp. 925-33. 
 
52 
Pimenova AA, Raj T and Goate AM (2018) 'Untangling Genetic Risk for Alzheimer's Disease', Biol 
Psychiatry, 83(4), pp. 300-310. 
Poliani PL, Wang Y, Fontana E, Robinette ML, Yamanishi Y, Gilfillan S and Colonna M (2015) 
'TREM2 sustains microglial expansion during aging and response to demyelination', J Clin Invest, 
125(5), pp. 2161-70. 
Porta S, Xu Y, Restrepo CR, Kwong LK, Zhang B, Brown HJ, Lee EB, Trojanowski JQ and Lee VM 
(2018) 'Patient-derived frontotemporal lobar degeneration brain extracts induce formation and 
spreading of TDP-43 pathology in vivo', Nat Commun, 9(1), pp. 4220. 
Pottier C, Wallon D, Rousseau S, Rovelet-Lecrux A, Richard AC, Rollin-Sillaire A, Frebourg T, 
Campion D and Hannequin D (2013) 'TREM2 R47H variant as a risk factor for early-onset Alzheimer's 
disease', J Alzheimers Dis, 35(1), pp. 45-9. 
Prada I, Ongania GN, Buonsanti C, Panina-Bordignon P and Meldolesi J (2006) 'Triggering receptor 
expressed in myeloid cells 2 (TREM2) trafficking in microglial cells: continuous shuttling to and from 
the plasma membrane regulated by cell stimulation', Neuroscience, 140(4), pp. 1139-48. 
Prusiner SB (1982) 'Novel proteinaceous infectious particles cause scrapie', Science, 216(4542), pp. 
136-44. 
Prusiner SB (1984) 'Some speculations about prions, amyloid, and Alzheimer's disease', N Engl J Med, 
310(10), pp. 661-3. 
Prusiner SB (1998) 'Prions', Proc Natl Acad Sci U S A, 95(23), pp. 13363-83. 
Prusiner SB (2012) 'Cell biology. A unifying role for prions in neurodegenerative diseases', Science, 
336(6088), pp. 1511-3. 
Prusiner SB (2013) 'Biology and genetics of prions causing neurodegeneration', Annu Rev Genet, 47, 
pp. 601-23. 
Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, Stoltze L, Calhoun ME, Jaggi F, 
Wolburg H, Gengler S, Haass C, Ghetti B, Czech C, Holscher C, Mathews PM and Jucker M (2006) 
'Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology', EMBO 
Rep, 7(9), pp. 940-6. 
Raha AA, Henderson JW, Stott SR, Vuono R, Foscarin S, Friedland RP, Zaman SH and Raha-
Chowdhury R (2017) 'Neuroprotective Effect of TREM-2 in Aging and Alzheimer's Disease Model', J 
Alzheimers Dis, 55(1), pp. 199-217. 
Ransohoff RM (2016) 'How neuroinflammation contributes to neurodegeneration', Science, 353(6301), 
pp. 777-83. 
Rapoport M, Dawson HN, Binder LI, Vitek MP and Ferreira A (2002) 'Tau is essential to beta -amyloid-
induced neurotoxicity', Proc Natl Acad Sci U S A, 99(9), pp. 6364-9. 
Rasmussen J, Mahler J, Beschorner N, Kaeser SA, Hasler LM, Baumann F, Nystrom S, Portelius E, 
Blennow K, Lashley T, Fox NC, Sepulveda-Falla D, Glatzel M, Oblak AL, Ghetti B, Nilsson KPR, 
Hammarstrom P, Staufenbiel M, Walker LC and Jucker M (2017) 'Amyloid polymorphisms constitute 
distinct clouds of conformational variants in different etiological subtypes of Alzheimer's disease', Proc 
Natl Acad Sci U S A, 114(49), pp. 13018-13023. 
 
53 
Rayaprolu S, Mullen B, Baker M, Lynch T, Finger E, Seeley WW, Hatanpaa KJ, Lomen-Hoerth C, 
Kertesz A, Bigio EH, Lippa C, Josephs KA, Knopman DS, White CL, 3rd, Caselli R, Mackenzie IR, 
Miller BL, Boczarska-Jedynak M, Opala G, Krygowska-Wajs A, Barcikowska M, Younkin SG, 
Petersen RC, Ertekin-Taner N, Uitti RJ, Meschia JF, Boylan KB, Boeve BF, Graff-Radford NR, 
Wszolek ZK, Dickson DW, Rademakers R and Ross OA (2013) 'TREM2 in neurodegeneration: 
evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease', 
Mol Neurodegener, 8, pp. 19. 
Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ and 
Fernandez-Hernando C (2010) 'MiR-33 contributes to the regulation of cholesterol homeostasis', 
Science, 328(5985), pp. 1570-3. 
Rebeck GW, Reiter JS, Strickland DK and Hyman BT (1993) 'Apolipoprotein E in sporadic Alzheimer's 
disease: allelic variation and receptor interactions', Neuron, 11(4), pp. 575-80. 
Rice HC, de Malmazet D, Schreurs A, Frere S, Van Molle I, Volkov AN, Creemers E, Vertkin I, Nys 
J, Ranaivoson FM, Comoletti D, Savas JN, Remaut H, Balschun D, Wierda KD, Slutsky I, Farrow K, 
De Strooper B and de Wit J (2019) 'Secreted amyloid-beta precursor protein functions as a GABABR1a 
ligand to modulate synaptic transmission', Science, 363(6423). 
Richter MC, Ludewig S, Winschel A, Abel T, Bold C, Salzburger LR, Klein S, Han K, Weyer SW, 
Fritz AK, Laube B, Wolfer DP, Buchholz CJ, Korte M and Muller UC (2018) 'Distinct in vivo roles of 
secreted APP ectodomain variants APPsalpha and APPsbeta in regulation of spine density, synaptic 
plasticity, and cognition', EMBO J, 37(11). 
Rodriguez GA, Tai LM, LaDu MJ and Rebeck GW (2014) 'Human APOE4 increases microglia 
reactivity at Abeta plaques in a mouse model of Abeta deposition', J Neuroinflammation, 11, pp. 111. 
Rovelet-Lecrux A, Hannequin D, Raux G, Meur NL, Laquerrière A, Vital A, Dumanchin C, Feuillette 
S, Brice A, Vercelletto M, Dubas F, Frebourg T and Campion D (2005) 'APP locus duplication causes 
autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy', Nature Genetics, 
38(1), pp. 24-26. 
Ruiz A, Dols-Icardo O, Bullido MJ, Pastor P, Rodriguez-Rodriguez E, Lopez de Munain A, de 
Pancorbo MM, Perez-Tur J, Alvarez V, Antonell A, Lopez-Arrieta J, Hernandez I, Tarraga L, Boada 
M, Lleo A, Blesa R, Frank-Garcia A, Sastre I, Razquin C, Ortega-Cubero S, Lorenzo E, Sanchez-Juan 
P, Combarros O, Moreno F, Gorostidi A, Elcoroaristizabal X, Baquero M, Coto E, Sanchez-Valle R, 
Clarimon J and dementia genetic Spanish c (2014) 'Assessing the role of the TREM2 p.R47H variant 
as a risk factor for Alzheimer's disease and frontotemporal dementia', Neurobiol Aging, 35(2), pp. 444 
e1-4. 
Rupp NJ, Wegenast-Braun BM, Radde R, Calhoun ME and Jucker M (2011) 'Early onset amyloid 
lesions lead to severe neuritic abnormalities and local, but not global neuron loss in APPPS1 transgenic 
mice', Neurobiol Aging, 32(12), pp. 2324 e1-6. 
Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N and Saido TC (2014) 'Single 
App knock-in mouse models of Alzheimer's disease', Nat Neurosci, 17(5), pp. 661-3. 
Saito T, Matsuba Y, Yamazaki N, Hashimoto S and Saido TC (2016) 'Calpain Activation in Alzheimer's 
Model Mice Is an Artifact of APP and Presenilin Overexpression', J Neurosci, 36(38), pp. 9933-6. 
Saito T, Suemoto T, Brouwers N, Sleegers K, Funamoto S, Mihira N, Matsuba Y, Yamada K, Nilsson 
P, Takano J, Nishimura M, Iwata N, Van Broeckhoven C, Ihara Y and Saido TC (2011) 'Potent 
amyloidogenicity and pathogenicity of Aβ43', Nature Neuroscience, 14(8), pp. 1023-1032. 
 
54 
Sanan DA, Weisgraber KH, Russell SJ, Mahley RW, Huang D, Saunders A, Schmechel D, Wisniewski 
T, Frangione B, Roses AD and et al. (1994) 'Apolipoprotein E associates with beta amyloid peptide of 
Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3', 
J Clin Invest, 94(2), pp. 860-9. 
Sasaguri H, Nilsson P, Hashimoto S, Nagata K, Saito T, De Strooper B, Hardy J, Vassar R, Winblad B 
and Saido TC (2017) 'APP mouse models for Alzheimer's disease preclinical studies', EMBO J, 36(17), 
pp. 2473-2487. 
Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, Rosi 
BL, Gusella JF, Crapper-MacLachlan DR, Alberts MJ and et al. (1993) 'Association of apolipoprotein 
E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease', Neurology, 43(8), pp. 1467-
72. 
Savage JC, Jay T, Goduni E, Quigley C, Mariani MM, Malm T, Ransohoff RM, Lamb BT and Landreth 
GE (2015) 'Nuclear Receptors License Phagocytosis by Trem2+ Myeloid Cells in Mouse Models of 
Alzheimer's Disease', Journal of Neuroscience, 35(16), pp. 6532-6543. 
Schlepckow K, Kleinberger G, Fukumori A, Feederle R, Lichtenthaler SF, Steiner H and Haass C 
(2017) 'An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects 
shedding and phagocytic function', EMBO Mol Med, 9(10), pp. 1356-1365. 
Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, 
Goldgaber D and Roses AD (1993) 'Increased amyloid beta-peptide deposition in cerebral cortex as a 
consequence of apolipoprotein E genotype in late-onset Alzheimer disease', Proc Natl Acad Sci U S A, 
90(20), pp. 9649-53. 
Schmitz C, Rutten BP, Pielen A, Schafer S, Wirths O, Tremp G, Czech C, Blanchard V, Multhaup G, 
Rezaie P, Korr H, Steinbusch HW, Pradier L and Bayer TA (2004) 'Hippocampal neuron loss exceeds 
amyloid plaque load in a transgenic mouse model of Alzheimer's disease', Am J Pathol, 164(4), pp. 
1495-502. 
Selkoe DJ (1991) 'Alzheimer's disease. In the beginning', Nature, 354(6353), pp. 432-3. 
Selkoe DJ (2001) 'Alzheimer's disease results from the cerebral accumulation and cytotoxicity of 
amyloid beta-protein', J Alzheimers Dis, 3(1), pp. 75-80. 
Selkoe DJ (2003) 'Folding proteins in fatal ways', Nature, 426(6968), pp. 900-4. 
Serneels L, Van Biervliet J, Craessaerts K, Dejaegere T, Horre K, Van Houtvin T, Esselmann H, Paul 
S, Schafer MK, Berezovska O, Hyman BT, Sprangers B, Sciot R, Moons L, Jucker M, Yang Z, May 
PC, Karran E, Wiltfang J, D'Hooge R and De Strooper B (2009) 'gamma-Secretase heterogeneity in the 
Aph1 subunit: relevance for Alzheimer's disease', Science, 324(5927), pp. 639-42. 
Serrano-Pozo A, Muzikansky A, Gomez-Isla T, Growdon JH, Betensky RA, Frosch MP and Hyman 
BT (2013) 'Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits 
in Alzheimer disease', J Neuropathol Exp Neurol, 72(6), pp. 462-71. 
Sessa G, Podini P, Mariani M, Meroni A, Spreafico R, Sinigaglia F, Colonna M, Panina P and Meldolesi 
J (2004) 'Distribution and signaling of TREM2/DAP12, the receptor system mutated in human 
polycystic lipomembraneous osteodysplasia with sclerosing leukoencephalopathy dementia', Eur J 
Neurosci, 20(10), pp. 2617-28. 
Shi Y and Holtzman DM (2018) 'Interplay between innate immunity and Alzheimer disease: APOE and 
TREM2 in the spotlight', Nat Rev Immunol, 18(12), pp. 759-772. 
 
55 
Sims R and van der Lee SJ and Naj AC and Bellenguez C and Badarinarayan N and Jakobsdottir J and 
Kunkle BW and Boland A and Raybould R and Bis JC and Martin ER and Grenier-Boley B and 
Heilmann-Heimbach S and Chouraki V and Kuzma AB and Sleegers K and Vronskaya M and Ruiz A 
and Graham RR and Olaso R and Hoffmann P and Grove ML and Vardarajan BN and Hiltunen M and 
Nothen MM and White CC and Hamilton-Nelson KL and Epelbaum J and Maier W and Choi SH, et 
al. (2017) 'Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate 
immunity in Alzheimer's disease', Nat Genet, 49(9), pp. 1373-1384. 
Slattery CF, Beck JA, Harper L, Adamson G, Abdi Z, Uphill J, Campbell T, Druyeh R, Mahoney CJ, 
Rohrer JD, Kenny J, Lowe J, Leung KK, Barnes J, Clegg SL, Blair M, Nicholas JM, Guerreiro RJ, 
Rowe JB, Ponto C, Zerr I, Kretzschmar H, Gambetti P, Crutch SJ, Warren JD, Rossor MN, Fox NC, 
Collinge J, Schott JM and Mead S (2014) 'R47H TREM2 variant increases risk of typical early-onset 
Alzheimer's disease but not of prion or frontotemporal dementia', Alzheimers Dement, 10(6), pp. 602-
608 e4. 
Song W, Hooli B, Mullin K, Jin SC, Cella M, Ulland TK, Wang Y, Tanzi RE and Colonna M (2016) 
'Alzheimer's disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent 
activation', Alzheimers Dement. 
Song W, Hooli B, Mullin K, Jin SC, Cella M, Ulland TK, Wang Y, Tanzi RE and Colonna M (2017) 
'Alzheimer's disease-associated TREM2 variants exhibit either decreased or increased ligand-dependent 
activation', Alzheimers Dement, 13(4), pp. 381-387. 
Song W, Joshita S, Zhou Y, Ulland TK, Gilfillan S and Colonna M (2018) 'Humanized TREM2 mice 
reveal microglia-intrinsic and -extrinsic effects of R47H polymorphism', J Exp Med, 215(3), pp. 745-
760. 
Sosna J, Philipp S, Albay R, 3rd, Reyes-Ruiz JM, Baglietto-Vargas D, LaFerla FM and Glabe CG 
(2018) 'Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces 
accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 
5XFAD mouse model of Alzheimer's disease', Mol Neurodegener, 13(1), pp. 11. 
Spangenberg EE, Lee RJ, Najafi AR, Rice RA, Elmore MR, Blurton-Jones M, West BL and Green KN 
(2016) 'Eliminating microglia in Alzheimer's mice prevents neuronal loss without modulating amyloid-
beta pathology', Brain, 139(Pt 4), pp. 1265-81. 
Stefano L, Racchetti G, Bianco F, Passini N, Gupta RS, Panina Bordignon P and Meldolesi J (2009) 
'The surface-exposed chaperone, Hsp60, is an agonist of the microglial TREM2 receptor', J Neurochem, 
110(1), pp. 284-94. 
Stohr J, Watts JC, Mensinger ZL, Oehler A, Grillo SK, DeArmond SJ, Prusiner SB and Giles K (2012) 
'Purified and synthetic Alzheimer's amyloid beta (Abeta) prions', Proc Natl Acad Sci U S A, 109(27), 
pp. 11025-30. 
Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS and Roses AD 
(1993a) 'Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 
allele in late-onset familial Alzheimer disease', Proc Natl Acad Sci U S A, 90(5), pp. 1977-81. 
Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel 
D, Saunders AM, Goldgaber D and Roses AD (1993b) 'Binding of human apolipoprotein E to synthetic 
amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease', Proc 
Natl Acad Sci U S A, 90(17), pp. 8098-102. 
Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, 
Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M and 
 
56 
Sommer B (1997) 'Two amyloid precursor protein transgenic mouse models with Alzheimer disease-
like pathology', Proc Natl Acad Sci U S A, 94(24), pp. 13287-92. 
Suarez-Calvet M, Araque Caballero MA, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, 
Danek A, Ewers M, Haass C and Dominantly Inherited Alzheimer N (2016a) 'Early changes in CSF 
sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal 
injury', Sci Transl Med, 8(369), pp. 369ra178. 
Suarez-Calvet M, Kleinberger G, Araque Caballero MA, Brendel M, Rominger A, Alcolea D, Fortea J, 
Lleo A, Blesa R, Gispert JD, Sanchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, 
Traschutz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, Van Broeckhoven C, Zetterberg H, 
Nellgard B, Blennow K, Crispin A, Ewers M and Haass C (2016b) 'sTREM2 cerebrospinal fluid levels 
are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with 
neuronal injury markers', EMBO Mol Med, 8(5), pp. 466-76. 
Suh J, Rivest AJ, Nakashiba T, Tominaga T and Tonegawa S (2011) 'Entorhinal cortex layer III input 
to the hippocampus is crucial for temporal association memory', Science, 334(6061), pp. 1415-20. 
Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman 
D, Bergeson J, Csako G, Levy JA, Bartko JJ and Cohen RM (2004) 'Cerebrospinal fluid beta-amyloid1-
42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele', Biol 
Psychiatry, 56(9), pp. 670-6. 
Thal DR, Schultz C, Dehghani F, Yamaguchi H, Braak H and Braak E (2000) 'Amyloid beta-protein 
(Abeta)-containing astrocytes are located preferentially near N-terminal-truncated Abeta deposits in the 
human entorhinal cortex', Acta Neuropathol, 100(6), pp. 608-17. 
Thelen M, Razquin C, Hernandez I, Gorostidi A, Sanchez-Valle R, Ortega-Cubero S, Wolfsgruber S, 
Drichel D, Fliessbach K, Duenkel T, Damian M, Heilmann S, Slotosch A, Lennarz M, Seijo-Martinez 
M, Rene R, Kornhuber J, Peters O, Luckhaus C, Jahn H, Hull M, Ruther E, Wiltfang J, Lorenzo E, 
Gascon J, Lleo A, Llado A, Campdelacreu J, Moreno F, Ahmadzadehfar H, Dementia Genetics Spanish 
C, Fortea J, Indakoetxea B, Heneka MT, Wetter A, Pastor MA, Riverol M, Becker T, Frolich L, Tarraga 
L, Boada M, Wagner M, Jessen F, Maier W, Clarimon J, Lopez de Munain A, Ruiz A, Pastor P and 
Ramirez A (2014) 'Investigation of the role of rare TREM2 variants in frontotemporal dementia 
subtypes', Neurobiol Aging, 35(11), pp. 2657 e13-2657 e19. 
Thornton P, Sevalle J, Deery MJ, Fraser G, Zhou Y, Stahl S, Franssen EH, Dodd RB, Qamar S, Gomez 
Perez-Nievas B, Nicol LS, Eketjall S, Revell J, Jones C, Billinton A, St George-Hyslop PH, Chessell I 
and Crowther DC (2017) 'TREM2 shedding by cleavage at the H157-S158 bond is accelerated for the 
Alzheimer's disease-associated H157Y variant', EMBO Mol Med, 9(10), pp. 1366-1378. 
Trojanowski JQ and Lee VM (1998) 'Aggregation of neurofilament and alpha-synuclein proteins in 
Lewy bodies: implications for the pathogenesis of Parkinson disease and Lewy body dementia', Arch 
Neurol, 55(2), pp. 151-2. 
Tsubuki S, Takaki Y and Saido TC (2003) 'Dutch, Flemish, Italian, and Arctic mutations of APP and 
resistance of Abeta to physiologically relevant proteolytic degradation', Lancet, 361(9373), pp. 1957-
8. 
Uchihara T, Duyckaerts C, He Y, Kobayashi K, Seilhean D, Amouyel P and Hauw JJ (1995) 'ApoE 
immunoreactivity and microglial cells in Alzheimer's disease brain', Neurosci Lett, 195(1), pp. 5-8. 
Ulrich JD, Finn MB, Wang Y, Shen A, Mahan TE, Jiang H, Stewart FR, Piccio L, Colonna M and 
Holtzman DM (2014) 'Altered microglial response to Abeta plaques in APPPS1-21 mice heterozygous 
for TREM2', Mol Neurodegener, 9, pp. 20. 
 
57 
Ulrich JD, Ulland TK, Mahan TE, Nystrom S, Nilsson KP, Song WM, Zhou Y, Reinartz M, Choi S, 
Jiang H, Stewart FR, Anderson E, Wang Y, Colonna M and Holtzman DM (2018) 'ApoE facilitates the 
microglial response to amyloid plaque pathology', J Exp Med, 215(4), pp. 1047-1058. 
Varnum MM, Clayton KA, Yoshii-Kitahara A, Yonemoto G, Koro L, Ikezu S and Ikezu T (2017) 'A 
split-luciferase complementation, real-time reporting assay enables monitoring of the disease-
associated transmembrane protein TREM2 in live cells', J Biol Chem, 292(25), pp. 10651-10663. 
Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, Vieira-Saecker A, Schwartz 
S, Santarelli F, Kummer MP, Griep A, Gelpi E, Beilharz M, Riedel D, Golenbock DT, Geyer M, Walter 
J, Latz E and Heneka MT (2017) 'Microglia-derived ASC specks cross-seed amyloid-beta in 
Alzheimer's disease', Nature, 552(7685), pp. 355-361. 
Verghese PB, Castellano JM, Garai K, Wang Y, Jiang H, Shah A, Bu G, Frieden C and Holtzman DM 
(2013) 'ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in 
physiological conditions', Proc Natl Acad Sci U S A, 110(19), pp. E1807-16. 
Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski 
JQ and Lee VM (2011) 'Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to 
synaptic dysfunction and neuron death', Neuron, 72(1), pp. 57-71. 
Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington 
CL, Bales KR, Paul SM and Holtzman DM (2008) 'Overexpression of ABCA1 reduces amyloid 
deposition in the PDAPP mouse model of Alzheimer disease', J Clin Invest, 118(2), pp. 671-82. 
Walker LC, Callahan MJ, Bian F, Durham RA, Roher AE and Lipinski WJ (2002) 'Exogenous induction 
of cerebral beta-amyloidosis in betaAPP-transgenic mice', Peptides, 23(7), pp. 1241-7. 
Walker LC and Jucker M (2015) 'Neurodegenerative diseases: expanding the prion concept', Annu Rev 
Neurosci, 38, pp. 87-103. 
Wang F, Wang X, Yuan CG and Ma J (2010) 'Generating a prion with bacterially expressed 
recombinant prion protein', Science, 327(5969), pp. 1132-5. 
Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML, Gilfillan S, Krishnan GM, 
Sudhakar S, Zinselmeyer BH, Holtzman DM, Cirrito JR and Colonna M (2015) 'TREM2 lipid sensing 
sustains the microglial response in an Alzheimer's disease model', Cell, 160(6), pp. 1061-71. 
Wang Y, Ulland TK, Ulrich JD, Song W, Tzaferis JA, Hole JT, Yuan P, Mahan TE, Shi Y, Gilfillan S, 
Cella M, Grutzendler J, DeMattos RB, Cirrito JR, Holtzman DM and Colonna M (2016) 'TREM2-
mediated early microglial response limits diffusion and toxicity of amyloid plaques', J Exp Med, 213(5), 
pp. 667-75. 
Watts JC, Condello C, Stohr J, Oehler A, Lee J, DeArmond SJ, Lannfelt L, Ingelsson M, Giles K and 
Prusiner SB (2014) 'Serial propagation of distinct strains of Abeta prions from Alzheimer's disease 
patients', Proc Natl Acad Sci U S A, 111(28), pp. 10323-8. 
Watts JC, Giles K, Grillo SK, Lemus A, DeArmond SJ and Prusiner SB (2011) 'Bioluminescence 
imaging of Abeta deposition in bigenic mouse models of Alzheimer's disease', Proc Natl Acad Sci U S 
A, 108(6), pp. 2528-33. 
Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA and Van Eldik LJ (2014) 'Using mice to model 
Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 
mouse models', Front Genet, 5, pp. 88. 
 
58 
Weisgraber KH (1990) 'Apolipoprotein E distribution among human plasma lipoproteins: role of the 
cysteine-arginine interchange at residue 112', J Lipid Res, 31(8), pp. 1503-11. 
Weisgraber KH, Mahley RW, Kowal RC, Herz J, Goldstein JL and Brown MS (1990) 'Apolipoprotein 
C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins 
(beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein', J 
Biol Chem, 265(36), pp. 22453-9. 
Weisgraber KH, Roses AD and Strittmatter WJ (1994) 'The role of apolipoprotein E in the nervous 
system', Curr Opin Lipidol, 5(2), pp. 110-6. 
Weisgraber KH and Shinto LH (1991) 'Identification of the disulfide-linked homodimer of 
apolipoprotein E3 in plasma. Impact on receptor binding activity', J Biol Chem, 266(18), pp. 12029-34. 
Wilson MJ, Lindquist JA and Trowsdale J (2000) 'DAP12 and KAP10 (DAP10)-Novel Transmembrane 
Adapter Proteins of the CD3ζ Family', Immunologic Research, 22(1), pp. 21-42. 
Wunderlich P, Glebov K, Kemmerling N, Tien NT, Neumann H and Walter J (2013) 'Sequential 
proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by 
ectodomain shedding and gamma-secretase-dependent intramembranous cleavage', J Biol Chem, 
288(46), pp. 33027-36. 
Wyss-Coray T and Rogers J (2012) 'Inflammation in Alzheimer disease-a brief review of the basic 
science and clinical literature', Cold Spring Harb Perspect Med, 2(1), pp. a006346. 
Xiang X, Piers TM, Wefers B, Zhu K, Mallach A, Brunner B, Kleinberger G, Song W, Colonna M, 
Herms J, Wurst W, Pocock JM and Haass C (2018) 'The Trem2 R47H Alzheimer's risk variant impairs 
splicing and reduces Trem2 mRNA and protein in mice but not in humans', Mol Neurodegener, 13(1), 
pp. 49. 
Xu G, Ran Y, Fromholt SE, Fu C, Yachnis AT, Golde TE and Borchelt DR (2015) 'Murine Abeta over-
production produces diffuse and compact Alzheimer-type amyloid deposits', Acta Neuropathol 
Commun, 3, pp. 72. 
Xu Q, Bernardo A, Walker D, Kanegawa T, Mahley RW and Huang Y (2006) 'Profile and regulation 
of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein 
gene to the ApoE locus', J Neurosci, 26(19), pp. 4985-94. 
Ye L, Fritschi SK, Schelle J, Obermuller U, Degenhardt K, Kaeser SA, Eisele YS, Walker LC, Baumann 
F, Staufenbiel M and Jucker M (2015a) 'Persistence of Abeta seeds in APP null mouse brain', Nat 
Neurosci, 18(11), pp. 1559-61. 
Ye L, Hamaguchi T, Fritschi SK, Eisele YS, Obermuller U, Jucker M and Walker LC (2015b) 
'Progression of Seed-Induced Abeta Deposition within the Limbic Connectome', Brain Pathol, 25(6), 
pp. 743-52. 
Yeh FL, Wang Y, Tom I, Gonzalez LC and Sheng M (2016) 'TREM2 Binds to Apolipoproteins, 
Including APOE and CLU/APOJ, and Thereby Facilitates Uptake of Amyloid-Beta by Microglia', 
Neuron, 91(2), pp. 328-40. 
Yuan P, Condello C, Keene CD, Wang Y, Bird TD, Paul SM, Luo W, Colonna M, Baddeley D and 
Grutzendler J (2016) 'TREM2 Haplodeficiency in Mice and Humans Impairs the Microglia Barrier 




Zhang XY, Yang ZL, Lu GM, Yang GF and Zhang LJ (2017) 'PET/MR Imaging: New Frontier in 
Alzheimer's Disease and Other Dementias', Front Mol Neurosci, 10, pp. 343. 
Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, Phatnani HP, Guarnieri P, Caneda 
C, Ruderisch N, Deng S, Liddelow SA, Zhang C, Daneman R, Maniatis T, Barres BA and Wu JQ 
(2014) 'An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of 
the cerebral cortex', J Neurosci, 34(36), pp. 11929-47. 
Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, Vogel H, Steinberg GK, Edwards 
MS, Li G, Duncan JA, 3rd, Cheshier SH, Shuer LM, Chang EF, Grant GA, Gephart MG and Barres BA 
(2016) 'Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals 
Transcriptional and Functional Differences with Mouse', Neuron, 89(1), pp. 37-53. 
Zhong L, Xu Y, Zhuo R, Wang T, Wang K, Huang R, Wang D, Gao Y, Zhu Y, Sheng X, Chen K, 
Wang N, Zhu L, Can D, Marten Y, Shinohara M, Liu C-C, Du D, Sun H, Wen L, Xu H, Bu G and Chen 
X-F (2019) 'Soluble TREM2 ameliorates pathological phenotypes by modulating microglial functions 
in an Alzheimer’s disease model', Nature Communications, 10(1). 
Ziegler-Waldkirch S, d'Errico P, Sauer JF, Erny D, Savanthrapadian S, Loreth D, Katzmarski N, Blank 
T, Bartos M, Prinz M and Meyer-Luehmann M (2018) 'Seed-induced Abeta deposition is modulated by 







I am incredibly grateful and blessed to have had the opportunities and experiences I had during 
my PhD. It would not have been possible without the supporting environment of my supervisor, 
team members, collaborators, friends and family. 
I would first like to thank my mentor and thesis advisor, Christian Haass. You have provided 
me with an abundance of support and guidance over the past several years that have allowed 
me to be successful. Your advice, encouragement, and sometimes what felt like a surreal 
amount of enthusiasm, were invaluable and helped me become confident in my abilities, for 
which I am truly appreciative. I only hope to continue to receive your guidance throughout my 
future scientific career.  
To Gernot Kleinberger, your suggestions helped tremendously shape my PhD. Thank you for 
lending me your ear, and your mentorship, which helped me become a better scientist. 
A heartfelt thanks to my thesis committee members, Melanie Meyer-Lühmann and Nikolaus 
Plesnila, for your invaluable insights throughout my PhD, and for gently pointing the way.  
Melanie, not only have you been a fantastic mentor to me, but you have also taught me how to 
mentor other people. Thank you for being such a great role model. 
To Matthias Brendel, special thanks for always replying to my emails lightning fast ;) It’s like 
you have a sixth sense for them! But also thank you for the fantastic scientific work, discussions 
and enthusiasm for our collaborative work. It was a pleasure! 
To Thomas Arzberger, thank you for teaching me how to navigate the human brain! I really 
enjoyed our time looking through the microscope carefully studying the samples together. You 
motivated me during difficult times when I needed words of encouragement. Thanks for all 
your support and useful advice. 
A very special thanks to my team members and colleagues, Kai Schlepckow, Anika 
Reifschneider, Anja Capell, Katie LaClaire, Brigitte Nuscher, Xianyuan Xiang, Yoshihiro 
Nihei, Ida Pesämaa, Bettina Brunner, Nadine Pettkus, Estrella Morenas, Marc Suarez-Calvet, 
Katrin Fellerer, Elizabeth Kremmer, Regina Federle, Fargol Mazaheri, Georg Werner, Jane 
Hettinger, Maryam Khojasteh-Fard, Mari Takalo, Michael Willem, Sven Lammich, Heike 
Hampel, Johannes Trambauer, Harald Steiner, Elisabeth Baloch, Gerda Mitteregger, Zhang 
Fang, Heike Jäckle Gashi, Manuela Schneider, Anne von Thaden, Stefanie Wurster and Claudia 
Ihbe for providing me with a very enjoyable work environment. You were a great group of 
individuals to work with, and provided a perfect mix of laughs and serious scientific 
discussions. 
I would like to thank all my collaborators, Monica Xiong, Dave Holtzman, Laura Sebastian 
Monasor, Alessio Colombo, Sabina Tahirovic, Natalie Katzmarski, Alireza Ghasemigharagoz, 
Ali Ertürk, Stephan Müller, Stefan Lichtenthaler, Maximiliam Deussing, Carola Focke, Axel 
Rominger, Peter Bartenstein, Jochen Herms, Stefan Grathwohl, Jonas Neher, Susanne 
Krasemann, Oleg Butovsky, Dieter Edbauer and Nicole Exner. Without you this project would 
not have been what it is today. I am sincerely grateful for all your time and effort. 
60 
 
To Sabine Odoy and Marcel Matt, without your maintenance nothing would work in the lab. 
Thank you for always helping even when I ordered countless antibodies and random surgery 
tools. 
To my Golden Girls, Alkmini Papadopoulou, Christine Schlosser and Charlotte Spitz. Thank 
you doesn't cut it. But since you already have an inflated version of self-worth, let me add to 
the pile—You are awesome, amazing, shockingly good looking, kind, thoughtful, always right, 
and most of all, just like me. 
My deep gratitude to my dear friends, Jasmine Rivett, Madeleine Helme, Alex Dospinescu, 
Laura Degeratu, Sara Ángel Gutiérrez and Diego Garcia Esteban. Your encouragement, support 
and faith means a lot to me. 
Finally, I would not be where I am today without my family, my parents, Shahin and Sunanda, 
my God parents, Anup and Nita, and my brother, Armand. You have supported me to the fullest 
in everything I have done throughout my life. I am blessed to have not one, but two incredibly 
supportive families. Chris, Toni, Robyn, Nick and Jamie, I am so grateful for all your love and 
support throughout these years. 
And to my husband, Adam. I simply could not have done this without you. Thank you for your 
patience (God knows I tested it), support and love through the long and stressful days, and for 
believing it would all be worth it. We did it! Thank you for everything, Always. 
 
 
 
 
 
